<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4 ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis"><meta name="DC.contributor" content="Bruce D. Roth" scheme="inventor"><meta name="DC.contributor" content="Warner-Lambert Company" scheme="assignee"><meta name="DC.date" content="1986-5-30" scheme="dateSubmitted"><meta name="DC.description" content="Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hypocholesterolemic agents. Pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions are also disclosed."><meta name="DC.date" content="1987-7-21" scheme="issued"><meta name="DC.relation" content="US:3983140" scheme="references"><meta name="DC.relation" content="US:4049495" scheme="references"><meta name="DC.relation" content="US:4137322" scheme="references"><meta name="DC.relation" content="US:4198425" scheme="references"><meta name="DC.relation" content="US:4255444" scheme="references"><meta name="DC.relation" content="US:4262013" scheme="references"><meta name="DC.relation" content="US:4375475" scheme="references"><meta name="citation_reference" content="Brown, et al.; J. Chem. Soc. Perkin I, (1976), pp. 1165 1170."><meta name="citation_reference" content="Brown, et al.; J. Chem. Soc. Perkin I, (1976), pp. 1165-1170."><meta name="citation_reference" content="Brown, et al.; New England Jour. of Med., vol. 305, No. 9, pp. 515 517, (1981)."><meta name="citation_reference" content="Brown, et al.; New England Jour. of Med., vol. 305, No. 9, pp. 515-517, (1981)."><meta name="citation_reference" content="Hulcher; Arch. Biochem. Biophys., vol. 146, pp. 422 427, (1971)."><meta name="citation_reference" content="Hulcher; Arch. Biochem. Biophys., vol. 146, pp. 422-427, (1971)."><meta name="citation_reference" content="Journal of the Americas Medical Assoc.; (1984), vol. 251, pp. 351 364, 365 374."><meta name="citation_reference" content="Journal of the Americas Medical Assoc.; (1984), vol. 251, pp. 351-364, 365-374."><meta name="citation_reference" content="Singer, et al.; Proc. Soc. Exper. Biol. Med.; vol. 102, pp. 370 373, (1959)."><meta name="citation_reference" content="Singer, et al.; Proc. Soc. Exper. Biol. Med.; vol. 102, pp. 370-373, (1959)."><meta name="citation_patent_number" content="US:4681893"><meta name="citation_patent_application_number" content="US:06/868,867"><link rel="canonical" href="http://www.google.com/patents/US4681893"/><meta property="og:url" content="http://www.google.com/patents/US4681893"/><meta name="title" content="Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis"/><meta name="description" content="Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hypocholesterolemic agents. Pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions are also disclosed."/><meta property="og:title" content="Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("zaftU_6XK4PhsATX4IKIDg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NOR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("zaftU_6XK4PhsATX4IKIDg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NOR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us4681893?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US4681893"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=SUMmBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS4681893&amp;usg=AFQjCNEXeMEZuezlnXRYTE1K-2grr3eZdA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US4681893.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US4681893.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US4681893" style="display:none"><span itemprop="description">Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hypocholesterolemic...</span><span itemprop="url">http://www.google.com/patents/US4681893?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis" title="Patent US4681893 - Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US4681893 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 06/868,867</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jul 21, 1987</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">May 30, 1986</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">May 30, 1986</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA1268768A1">CA1268768A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE3767770D1">DE3767770D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE19775019I2">DE19775019I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0247633A1">EP0247633A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0247633B1">EP0247633B1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">06868867, </span><span class="patent-bibdata-value">868867, </span><span class="patent-bibdata-value">US 4681893 A, </span><span class="patent-bibdata-value">US 4681893A, </span><span class="patent-bibdata-value">US-A-4681893, </span><span class="patent-bibdata-value">US4681893 A, </span><span class="patent-bibdata-value">US4681893A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Bruce+D.+Roth%22">Bruce D. Roth</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Warner-Lambert+Company%22">Warner-Lambert Company</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US4681893.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US4681893.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US4681893.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (7),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (10),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (313),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (12),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (10)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/4681893&usg=AFQjCNFpPj6voDHcLIiIaj6X8WiM87V0-w">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D4681893&usg=AFQjCNGFbnKWahKM7LtXhm8SoXbZ1ZBgaw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D4681893A%26KC%3DA%26FT%3DD&usg=AFQjCNHy48MvJG44hKcWiW7JVASYxwhPMw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT53221735" lang="EN" load-source="patent-office">Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis</invention-title></span><br><span class="patent-number">US 4681893 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA36689600" lang="EN" load-source="patent-office"> <div class="abstract">Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hypocholesterolemic agents. Pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions are also disclosed.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(20)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US4681893-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US4681893-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(9)</span></span></div><div class="patent-text"><div mxw-id="PCLM58850280" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>I claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A compound of structural formula I ##STR17## wherein X is --CH<sub>2</sub> --, --CH<sub>2</sub> CH<sub>2</sub> --, --CH<sub>2</sub> CH<sub>2</sub> CH<sub>2</sub> --, or --CH<sub>2</sub> CH(CH<sub>3</sub>)--;<div class="claim-text">R<sub>1</sub> is<div class="claim-text">1-naphthyl;</div> <div class="claim-text">2-naphthyl;</div> <div class="claim-text">cyclohexyl;</div> <div class="claim-text">norbornenyl;</div> <div class="claim-text">phenyl;</div> <div class="claim-text">phenyl substituted with<div class="claim-text">fluorine,</div> <div class="claim-text">chlorine,</div> <div class="claim-text">bromine,</div> <div class="claim-text">hydroxyl,</div> <div class="claim-text">trifluoromethyl,</div> <div class="claim-text">alkyl of from one to four carbon atoms,</div> <div class="claim-text">alkoxy of from one to four carbon atoms, or</div> <div class="claim-text">alkanoyloxy of from two to eight carbon atoms;</div> </div> </div> <div class="claim-text">either of R<sub>2</sub> or R<sub>3</sub> is --CONR<sub>5</sub> R<sub>6</sub> where R<sub>5</sub> and R<sub>6</sub> are independently<div class="claim-text">hydrogen;</div> <div class="claim-text">alkyl of from one to six carbon atoms;</div> <div class="claim-text">phenyl;</div> <div class="claim-text">phenyl substituted with<div class="claim-text">fluorine,</div> <div class="claim-text">chlorine,</div> <div class="claim-text">bromine,</div> <div class="claim-text">cyano,</div> <div class="claim-text">trifluoromethyl, or</div> <div class="claim-text">carboalkoxy of from three to eight carbon atoms;</div> </div> </div> <div class="claim-text">and the other of R<sub>2</sub> or R<sub>3</sub> is<div class="claim-text">hydrogen;</div> <div class="claim-text">alkyl of from one to six carbon atoms;</div> <div class="claim-text">cyclopropyl;</div> <div class="claim-text">cyclobutyl;</div> <div class="claim-text">cyclopentyl;</div> <div class="claim-text">cyclohexyl;</div> <div class="claim-text">phenyl; or</div> <div class="claim-text">phenyl substituted with<div class="claim-text">fluorine,</div> <div class="claim-text">chlorine,</div> <div class="claim-text">bromine,</div> <div class="claim-text">hydroxyl,</div> <div class="claim-text">trifluoromethyl,</div> <div class="claim-text">alkyl of from one to four carbon atoms,</div> <div class="claim-text">alkoxy of from one to four carbon atoms, or</div> <div class="claim-text">alkanoyloxy of from two to eight carbon atoms;</div> </div> </div> <div class="claim-text">R<sub>4</sub> is<div class="claim-text">alkyl of from one to six carbon atoms;</div> <div class="claim-text">cyclopropyl;</div> <div class="claim-text">cyclobutyl;</div> <div class="claim-text">cyclopentyl;</div> <div class="claim-text">cyclohexyl; or</div> <div class="claim-text">trifluoromethyl;</div> </div> <div class="claim-text">or a hydroxy acid or pharmaceutically acceptable salts thereof, corresponding to the opened lactone ring of the compounds of structural formula I above.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A compound as defined by claim 1 wherein X is --CH<sub>2</sub> CH<sub>2</sub> --.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A compound as defined by claim 2 wherein R<sub>1</sub> is phenyl; or phenyl substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A compound as defined by claim 2 wherein R<sub>4</sub> is alkyl of from one to six carbon atoms.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A compound as defined by claim 1 having the name trans-(±)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A compound as defined by claim 1 having the name trans-2-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-5-trifluoromethyl-1H-pyrrole-3-carboxamide.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. A compound as defined by claim 1 having the name trans-5-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-trifluoromethyl-1H-pyrrole-3-carboxamide.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. A pharmaceutical composition, useful as a hypocholesterolemic agent, comprising a hypocholesterolemic effective amount of a compound in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A method of inhibiting cholesterol biosynthesis in a patient in need of such treatment by administering a pharmaceutical composition as defined by claim 8.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES65602809" lang="EN" load-source="patent-office" class="description">
    <heading>BACKGROUND OF THE INVENTION</heading> <p>The present invention is related to compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents. More particularly, this invention concerns certain trans-6-[2-(3- or 4-carboxamidosubstitutedpyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase), pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical compositions.</p>
    <p>High levels of blood cholesterol and blood lipids are conditions involved in the onset of arteriosclerosis. It is well known that inhibitors of HMG-CoA reductase are effective in lowering the level of blood plasma cholesterol, especially low density lipoprotein cholesterol (LDL-C), in man (cf. M. S. Brown and J. L. Goldstein, New England Journal of Medicine, 305, No. 9, 515-517 (1981). It has now been established that lowering LDL-C levels affords protection from coronary heart disease (cf. Journal of the American Medical Association, 251, No. 3, 351-374 (1984).</p>
    <p>Moreover, it is known that certain derivatives of mevalonic acid (3,5-dihydroxy-3-methylpentanoic acid) and the corresponding ring-closed lactone form, mevalonolactone, inhibit the biosynthesis of cholesterol (cf. F. M. Singer et al., Proc. Soc. Exper. Biol. Med., 102: 370 (1959) and F. H. Hulcher, Arch. Biochem. Biophys., 146: 422 (1971)).</p>
    <p>U.S. Pat. Nos. 3,983,140; 4,049,495 and 4,137,322 disclose the fermentative production of a natural product, now called compactin, having an inhibitory effect on cholesterol biosynthesis. Compactin has been shown to have a complex structure which includes a mevalonolactone moiety (Brown et al., J. Chem. Soc. Perkin I (1976) 1165.</p>
    <p>U.S. Pat. No. 4,255,444 to Oka et al. discloses several synthetic derivatives of mevalonolactone having antilipidemic activity.</p>
    <p>U.S. Pat. Nos. 4,198,425 and 4,262,013 to Mitsue et al. disclose aralkyl derivatives of mevalonolactone which are useful in the treatment of hyperlipidemia.</p>
    <p>U.S. Pat. no. 4,375,475 to Willard et al. discloses certain substituted 4-hydroxytetrahydropyran-2-ones which, in the 4(R)-trans-stereoisomeric form, are inhibitors of cholesterol biosynthesis.</p>
    <p>Published PCT application No. WO 84/01231 discloses certain indole analogs and derivatives of mevalonolactone having utility as hypolipoproteinemic and antiatherosclerotic agents.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>In accordance with the present invention, there are provided certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened hydroxy-acids derived therefrom which are potent inhibitors of cholesterol biosynthesis by virtue of their ability to inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase).</p>
    <p>In particular, in its broadest aspect the present invention provides compounds of structural formula I ##STR1## wherein X is --CH<sub>2</sub> --, --CH<sub>2</sub> CH<sub>2</sub> --, --CH<sub>2</sub> CH<sub>2</sub> CH<sub>2</sub> -- or --CH<sub>2</sub> CH(CH<sub>3</sub>)--.</p>
    <p>R<sub>1</sub> is 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; phenyl, phenyl substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms.</p>
    <p>Either R<sub>2</sub> or R<sub>3</sub> is --CONR<sub>5</sub> R<sub>6</sub> where R<sub>5</sub> and R<sub>6</sub> are independently hydrogen; alkyl of from one to six carbon atoms; 2-, 3-, or 4-pyridinyl; phenyl; phenyl substituted with fluorine, chlorine, bromine, cyano, trifluoromethyl, or carboalkoxy of from three to eight carbon atoms; and the other of R<sub>2</sub> or R<sub>3</sub> is hydrogen; alkyl of from one to six carbon atoms; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; or phenyl substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms.</p>
    <p>R<sub>4</sub> is alkyl of from one to six carbon atoms; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; or trifluoromethyl.</p>
    <p>Also contemplated as falling within the scope of the present invention are the hydroxy acids, and pharmaceutically acceptable salts thereof, derived from the opening of the lactone ring of the compounds of structural formula I above.</p>
    <p>In another aspect of the present invention, there is provided a method of preparing the compounds of structural formula I above which comprises the steps of</p>
    <p>(a) first reacting a substituted [(pyrrol-1-yl)alkyl]aldehyde compound of the formula ##STR2##  with the dilithio or sodio-lithio salt of methyl acetoacetate to form a compound of the structure ##STR3## (b) reducing the product of step (a) with a trialkylborane compound such as tributylborane in the presence of sodium borohydride in an inert solvent;</p>
    <p>(c) oxidizing the product of step (b) with alkaline aqueous hydrogen peroxide solution to produce a compound of the formula ##STR4##  and (d) cyclizing the product step (c) to a lactone of formula I above by heating in an inert solvent such as toluene or, alternatively converting the product of step (c) to a pharmaceutically acceptable salt by conventional methods.</p>
    <p>In yet another aspect, the present invention provides pharmaceutical compositions useful as hypolipidemic or hypocholesterolemic agents comprising a hypolipidemic or hypocholesterolemic effective amount of a compound in accordance with this invention as set forth above, in combination with a pharmaceutically acceptable carrier.</p>
    <p>In another aspect, the present invention provides a method of inhibiting cholesterol biosynthesis in a patient in need of such treatment by administering an effective amount of a pharmaceutical composition as defined above.</p>
    <heading>DETAILED DESCRIPTION</heading> <p>The compounds of the present invention comprise a class of trans-6-[2-(3- or 4-carboxamidosubstituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones in which the pyran-2-one moiety is attached, through an alkyl chain, to the substituted pyrrole nucleus at the nitrogen, or 1-position, of the pyrrole. The alkyl group may be methylene, ethylene, propylene, or methylethylene. The preferred alkyl chain linking the substituted pyrrole nucleus and the 4-hydroxypyran-2-one ring is ethylene.</p>
    <p>The compounds of structural formula I above possess two asymmetric carbon centers, one at the 4-hydroxy position of the pyran-2-one ring, and the other at the 6-position of the pyran-2-one ring where the alkylpyrrole group is attached. This asymmetry gives rise to four possible isomers, two of which are the R-cis- and S-cis-isomers and the other two of which are the R-trans- and S-trans-isomers. This invention contemplates only the trans- form of the compounds of formula I above.</p>
    <p>In the compounds of the present invention, position 2 of the substituted pyrrole nucleus is substituted with 1-naphthyl; 2-naphthyl; cyclohexyl; norbornenyl; 2-, 3-, or 4-pyridinyl; phenyl, phenyl substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms. Preferred substituent groups at the 2-position of the pyrrole nucleus are phenyl and substituted phenyl.</p>
    <p>In the compounds of this invention, position 5 of the pyrrole nucleus is substituted with alkyl of from one to six carbon atoms; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; or trifluoromethyl. Preferred substituents are alkyl or trifluoromethyl with isopropyl being particularly preferred.</p>
    <p>The preferred reaction sequence which is used to prepare compounds of the present invention involves the cycloaddition of a disubstituted acetylene, in which one substituent is carboxamido or N-substituted carboxamido, to an appropriately substituted N-acylaminocarboxylic acid to form a substituted pyrrole. This addition may occur in either of two ways, leading to a substituted pyrrole addition product in which the carboxamido substituent resides on either carbon 3 or 4 of the pyrrole nucleus.</p>
    <p>Thus, in compounds of the present invention, the substituent at either position 3 or 4 of the pyrrole nucleus is --CONR<sub>5</sub> R<sub>6</sub> where R<sub>5</sub> and R<sub>6</sub> are independently hydrogen; alkyl of from one to six carbon atoms; 2-, 3-, or 4-pyridinyl; phenyl; phenyl substituted with fluorine, chlorine, bromine, cyano, trifluoromethyl, or carboalkoxy of from three to eight carbon atoms and the other of the two positions is unsubstituted or is substituted with alkyl of from one to six carbon atoms; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; phenyl; or phenyl substituted with fluorine, chlorine, bromine, hydroxyl; trifluoromethyl; alkyl of from one to four carbon atoms, alkoxy of from one to four carbon atoms, or alkanoyloxy of from two to eight carbon atoms.</p>
    <p>Preferred groups for R<sub>5</sub> and R<sub>6</sub> are hydrogen, phenyl, or substituted phenyl. In a particularly preferred group of compounds within the present invention, R<sub>5</sub> is hydrogen and R<sub>6</sub> is phenyl or substituted phenyl.</p>
    <p>The compounds of this invention are prepared by the general reaction scheme outlined in Reaction Sequence 1 which takes advantage of the chemistry of mesionic compounds of the type described originally by R. Huisgen et al., Ang. Chem. Int. Ed., 3: 136 (1964).</p>
    <p>The known, or readily prepared, α-haloesters of structural formula II are reacted with the known 2-[1-(2-aminoalkyl)]-1,3-dioxalane, III, in the presence of an acid scavenger such as triethylamine to produce the N-alkyl-α-aminoesters, IV. The aminoesters, IV are ##STR5## acylated with an acid halide and subsequently hydrolyzed in aqueous base solution to produce the N-acyl-N-alkyl aminoacids, V.</p>
    <p>The N-acyl-N-alkyl aminoacids, V, are reacted with the appropriately substituted carboxamido acetylenic compounds, VI, in the presence of an acid anhydride to produce a mixture of the isomeric substituted pyrrole compounds VIIa and VIIb. Depending upon the substituents present, this cyclo-addition reaction affords differing ratios of the two products. For example, in the situation where R<sub>4</sub> is trifluoromethyl, the reaction yields roughly equimolar amounts of the two isomeric products. In such situations, the two isomeric products are separated by chromatographic techniques well known in the art, and subsequently further purified, if desired, by recrystallization. On the other hand, in the case where R<sub>4</sub> is 1-methylethyl, the cyclo-addition reaction yields predominantly one product which can be purified by recrystallization alone.</p>
    <p>Hydrolysis of the acetal function of compounds VIIa and VIIb in aqueous acid solution affords the aldehydes VIIIa and VIIIb. The aldehydes, VIII, are further converted to compounds of the present invention by the processes depicted in Reaction Sequence 2.</p>
    <p>The aldehyde compounds, VIII, are reacted with the dilithium or lithio-sodio salt of methyl acetoacetate to produce the corresponding 7-(substituted-pyrrolyl)-5-hydroxy-3-oxoheptanoates, IX. The heptanoates, IX, are dissolved in a polar solvent such as tetrahydrofuran, through which a small amount of air has been bubbled. A slight excess of a trialkylborane, such as tributylborane, is added to the mixture which is then cooled to a temperature of preferably between about 0° C. and -78° C. after which sodium borohydride is added.</p>
    <p>The mixture is stirred for about one to two hours and then oxidized by the addition of basic aqueous hydrogen peroxide solution. The reaction produces the 7-(substituted-pyrrolyl)-3,5-dihydroxyheptanoic acids, ##STR6## X, in which the product contains a predominance of the desired R*,R* configuration at carbon atoms three and five which bear the hydroxy groups.</p>
    <p>The acids may be converted to a corresponding pharmaceutically acceptable salt by conventional means, if desired, or cyclized to the trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones, I, by dehydration in an inert solvent such as refluxing toluene with azeotropic removal of water. This cyclization step has been found to produce material containing from 85-90% of the desired trans-configuration of the 4-hydroxy group relative to the 6-(substituted-pyrrol-1-yl)alkyl group on the pyran-2-one lactone ring.</p>
    <p>The ring-opened hydroxy acids of structural formula II above are intermediates in the synthesis of the lactone compounds of formula I and may be used in their free acid form or in the form of a pharmaceutically acceptable metal or amine salt in the pharmaceutical method of the present invention. These acids react to form pharmaceutically acceptable metal and amine salts. The term "pharmaceutically acceptable metal salt" contemplates salts formed with the sodium, potassium, calcium, magnesium, aluminum, iron, and zinc ions. The term "pharmaceutically acceptable amine salt" contemplates salts with ammonia and organic nitrogenous bases strong enough to form salts with carboxylic acids. Bases useful for the formation of pharmaceutically acceptable nontoxic base addition salts of compounds of the present invention form a class whose limits are readily understood by those skilled in the art.</p>
    <p>The free acid form of compounds of the present invention may be regenerated from the salt form, if desired, by contacting the salt with a dilute aqueous solution of an acid such as hydrochloric acid.</p>
    <p>The base addition salts may differ from the free acid forms of the compounds of this invention in such physical characteristics as solubility and melting point, but are otherwise considered equivalent to the free acid form for the purposes of this invention.</p>
    <p>The compounds of the present invention may exist in solvated or unsolvated form. In general, the solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for the purposes of this invention.</p>
    <p>The compounds of this invention are useful as hypocholesterolemic or hypolipidemic agents by virtue of their ability to inhibit the biosynthesis of cholesterol through inhibition of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase).</p>
    <p>The ability of compounds of the present invention to inhibit the biosynthesis of cholesterol was measured by two methods. A first method (designated CSI screen) utilized the procedure described by R. E. Dugan et al., Archiv. Biochem. Biophys., (1972), 152, 21-27. In this method, the level of HMG-CoA enzyme activity in standard laboratory rats is increased by feeding the rats a chow diet containing 5% cholestyramine for four days, after which the rats are sacrificed.</p>
    <p>The rat livers are homogenized, and the incorporation of cholesterol-<sup>14</sup> C-acetate into nonsaponifiable lipid by the rat liver homogenate is measured. The micromolar concentration of compound required for 50% inhibition of sterol synthesis over a one-hour period is measured, and expressed as an IC<sub>50</sub> value.</p>
    <p>A second method (designated COR screen) employed the procedure detailed by T. Kita, et al., J. Clin. Invest., (1980), 66: 1094-1100. In this method, the amount of <sup>14</sup> C-HMG-CoA converted to <sup>14</sup> C-mevalonate in the presence of a purified enzyme preparation of HMG-CoA reductase was measured. The micromolar concentration of compound required for 50% inhibition of cholesterol synthesis was measured and recorded as an IC<sub>50</sub> value.</p>
    <p>The activity of several representative examples of compounds in accordance with the present invention appears in Table 1, and is compared with that of the prior art compound, compactin.</p>
    <p>For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersable granules, capsules, cachets, and suppositories.</p>
    <p>A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.</p>
    <p>In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.</p>
    <p>For preparing suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted, and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.</p>
    <p>Powders and tablets preferably contain between about 5 to about 70% by weight of the active ingredient. Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.</p>
    <p>The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 1__________________________________________________________________________ ##STR7##                                               IC<sub>50</sub>                                               (Micromoles/liter)Compound X      R<sub>1</sub>  R<sub>2</sub>     R<sub>3</sub>    R<sub>4</sub>                                               CSI   COR__________________________________________________________________________1     CH<sub>2</sub> CH<sub>2</sub>         ##STR8##                  ##STR9##                              ##STR10## CH(CH<sub>3</sub>)<sub>2</sub>                                               0.035 0.0502     CH<sub>2</sub> CH<sub>2</sub>         ##STR11##                  ##STR12##                              ##STR13## CF<sub>3</sub>                                               0.40  0.403     CH<sub>2</sub> CH<sub>2</sub>         ##STR14##                  ##STR15##                              ##STR16## CF<sub>3</sub>                                               0.018 0.020Compactin (Prior art)                               0.026 0.028__________________________________________________________________________</pre>
    
    <p>surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.</p>
    <p>Liquid form preparations include solutions suitable for oral or parenteral administration, or suspensions and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol may be mentioned as examples of liquid preparations suitable for parenteral administration.</p>
    <p>Sterile solutions may be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.</p>
    <p>Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.</p>
    <p>Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.</p>
    <p>In therapeutic use as hypolipidemic or hypocholesterolemic agents, the compounds utilized in the pharmaceutical method of this invention are administered to the patient at dosage levels of from 40 mg to 600 mg per day. For a normal human adult of approximately 70 kg or body weight, this translates to a dosage of from about 0.5 mg/kg to about 8.0 mg/kg of body weight per day.</p>
    <p>The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of optimum dosages for a particular situation is within the skill of the art.</p>
    <p>The following examples illustrate particular methods for preparing compounds in accordance with this invention. These examples are illustrative and are not to be read as limiting the scope of the invention as it is defined by the appended claims.</p>
    <heading>EXAMPLE 1</heading> <heading>Preparation of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo2H-pyran-2-yl)ethyl]-pyrrole-3-carboxamide</heading> <p>Step A: Preparation of α-[[2-(1,3-dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid, ethyl ester</p>
    <p>A solution of 26 g (220 mmol) of 2-[1-(2-aminoethyl)]-1,3-dioxalane in 50 ml of acetonitrile was added at room temperature with stirring to a solution of 200 mmol of α-bromo-4-fluorobenzeneacetic acid, ethyl ester (J. W. Epstein et al., J. Med. Chem., 24: 481-490 (1981)) and 42 ml (300 mmol) of triethylamine in 350 ml of acetonitrile. The resulting mixture was stirred at room temperature overnight and then poured into 500 ml of diethyl ether. The resulting suspension was extracted with 300 ml of water and then twice with 300-ml portions of 2M hydrochloric acid. The combined extracts were made basic with 25% aqueous sodium hydroxide solution and extracted twice with 500-ml portions of ethyl acetate. The ethyl acetate extracts were combined, washed successively with water and brine, and then dried over anhydrous magnesium sulfate. The drying agent was removed by filtration, and the residue concentrated to yield 49.5 g of α-[[2-(1,3-dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid, ethyl ester.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of the product in deuterochloroform exhibited signals at 1.18 (triplet, 3H, J=7 Hz); 1.85 (multiplet, 2H); 2.20 (broad singlet, 1H); 2.6 (multiplet, 2H); 3.85 (multiplet, 4H); 4.1 (quartet, 2H, J=7 Hz); 4.22 (singlet, 1H); 4.83 (triplet, 1H, J=4.5 Hz); and 6.8-7.3 (multiplet, 4H) parts per million downfield from tetramethylsilane.</p>
    <p>Step B. Preparation of α-[[2-(1,3-dioxolan-2-yl)ethyl]-(2-methyl-1-oxopropyl)amino]-4-fluorobenzeneacetic acid, ethyl ester.</p>
    <p>Thirty grams (100 mmol) of α-[[2-(1,3-dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid, ethyl ester from Step A were dissolved in 200 ml of dichloromethane together with 28.6 ml (205 mmol) of triethylamine and the resulting mixture was cooled to 0° C. under dry nitrogen. A solution of 11 ml (105 mmol) of isobutyryl chloride in 50 ml of dichloromethane was slowly added with stirring. After addition was complete, the mixture was stirred for an additional 60 minutes and then poured into 100 ml of diethyl ether. The ether solution was washed successively with portions of water, 2M hydrochloric acid, sodium bicarbonate solution, and brine, and then dried over anhydrous magnesium sulfate. Evaporation of the solvents yielded 35 g of α-[[2-(1,3-dioxolan-2-yl)-ethyl]-(2-methyl-1-oxopropyl)amino]-4-fluorobenzene-acetic acid, ethyl ester.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of a deuterochloroform solution of the product exhibited signals at 1.2 (multiplet, 9H); 1.7 (multiplet, 2H); 2.85 (multiplet, 1H); 3.35 (multiplet, 2H); 3.80 (multiplet, 4H); 4.20 (quartet, 2H, J=7 Hz); 4.60 (triplet, 1H, J=4.5 Hz); 5.81 (singlet, 1H); and 6.8-7.3 (multiplet, 4H) parts per million downfield from tetramethylsilane.</p>
    <p>Step C. Preparation of α-[[2-(1,3-dioxolan-2-yl)ethyl]-(2-methyl-1-oxopropyl)amino]-4-fluorobenzeneacetic acid</p>
    <p>A solution of 35 g (95.3 mmol) of the ester from Step B and 12 g (300 mmol) of sodium hydroxide in 480 ml of 5:1 methanol water was heated under reflux and stirred for two hours. The solution was cooled to room temperature, concentrated, and diluted by the addition of 500 ml of water. The resulting solution was extracted with ether and the aqueous layer was acidified with ice-cold 6M hydrochloric acid and then extracted twice with 300-ml portions of ethyl acetate.</p>
    <p>The combined extracts were washed with brine, dried over anhydrous magnesium sulfate, and evaporated to yield 30 g of crude α-[[2-(1,3-dioxolan-2-yl)ethyl]-(2-methyl-1-oxopropyl)amino]-4-fluorobenzeneacetic acid which was used without further purification.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of a deuterochloroform solution of the product exhibited signals at 1.11 (doublet, 6H, J=7 Hz); 1.4-1.9 (multiplet, 2H); 2.85 (multiplet, 1H); 3.32 (multiplet, 2H); 3.75 (multiplet, 4H); 4.52 (triplet, 1H, J=4.5 Hz); 5.73 (singlet, 1H); and 6.8-7.3 (multiplet, 4H) parts per million downfield from tetramethylsilane.</p>
    <p>Step D. Preparation of N,3-diphenylpropynamide</p>
    <p>A solution of 171 mmol of dicyclohexylcarbodiimide in 250 ml of dichloromethane was added dropwise over a two hour period at 0° C. to a suspension of 171 mmol of propiolic acid, 179.6 mmol of aniline, and 5 mmol of 4-dimethylaminopyridine in 400 ml of dichloromethane. After addition was complete, the mixture was stirred for an additional 30 minutes and then diluted with diethyl ether. The resulting mixture was filtered through silica gel, concentrated, and the residue recrystallized to provide 30.5 g of N,3-diphenyl-2-propynamide, mp 122°-123° C.</p>
    <p>Analyzed for C<sub>15</sub> H<sub>13</sub> NO: Calc.: C, 80.69%; H, 5.87%; N, 6.27%; Found: C, 80.54%; H, 5.58%; N, 6.52%.</p>
    <p>The infrared spectrum of a KBr pellet of the compound showed principal peaks at 2215, 1630, 1595,1549, 1490, 1445, 1330, 756, and 691 reciprocal centimeters.</p>
    <p>Step E. Preparation of 1-[2-(1,3-dioxalan-2-yl)ethyl]-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide</p>
    <p>A solution of 95 g (280 mmol) of α-[[2-(1,3-dioxolan-2-yl)ethyl]-(2-methyl-1-oxopropyl)amino]-4-fluorobenzeneacetic acid, prepared as described in Step C above, and 98 g (439 mmol) of N,2-diphenylpropenoic carboxamide, prepared as described in Step D above, was heated at 90° C. with stirring for four hours, (Vigorous gas evolution occurred for two hours.) After this time, the mixture was cooled to room temperature and chromatographed twice on silica gel, eluting with 4:1 hexane:ethyl acetate to separate the product (R<sub>f</sub> =0.35) from the starting material (R<sub>f</sub> =0.5).</p>
    <p>Recrystallization of the product from isopropyl ether provided 59.5 g (119.3 mmol) of 1-[2-(1,3-dioxalan-2-yl)ethyl]-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide, mp 159°-162° C.</p>
    <p>Analyzed for C<sub>31</sub> H<sub>31</sub> FN<sub>2</sub> O<sub>3</sub> : Calc.: C, 74.68%; H, 6.27%; N, 5.62%; Found: C, 75.04%; H, 6.12%; N, 5.89%.</p>
    <p>Step F. Preparation of 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide</p>
    <p>A solution of 59 g (118.3 mmol) of 1-[2-(1,3-dioxalan-2-yl)ethyl]-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide, from Step E above, and 0.4 ml of concentrated hydrochloric acid in 1200 ml of anhydrous ethanol was heated under reflux with stirring for 24 hours. After this time the mixture was cooled to room temperature, concentrated, and the residue taken up in 1200 ml of 3:1 acetone:water and 5 g of p-toluenesulfonic acid was added. This mixture was heated under reflux with stirring for two days after which time the solution was cooled to room temperature and partitioned between 1 liter of diethyl ether and 200 ml of brine solution.</p>
    <p>The organic phase was separated, washed successively with sodium bicarbonate solution and brine, dried over anhydrous magnesium sulfate and concentrated. The oil which resulted was dissolved in the minimum amount required of hot isopropyl ether. The crystals which formed upon cooling were collected by filtration to yiled 36.8 g of 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide. A further crop of 9.8 g of crystals were obtained from the mother liquor.</p>
    <p>Analyzed for C<sub>29</sub> H<sub>27</sub> FN<sub>2</sub> O<sub>3</sub> : Calc.: C, 76.63%; H, 5.99%; N, 6.16%; Found: C, 76.48%; H, 6.20%; N, 6.14%.</p>
    <p>Step G. Preparation of 2-(4-fluorophenyl)-δ-hydroxy-5-(1-methylethyl)-β-oxo-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, methyl ester</p>
    <p>A solution of methyl acetoacetate (26.4 ml, 243 mmol) in 250 ml of anhydrous tetrahydrofuran was added dropwise to a stirred suspension of hexane-washed sodium hydride (6.4 g, 267 mmol) in 200 ml of tetrahydrofuran at 0° C. When gas evolution was complete, 97.2 ml of 2.5M n-butyl lithium was added dropwise over a period of 60 minutes.</p>
    <p>The resulting solution was stirred for 30 minutes at 0° C. and then cooled to -78° C. after which a solution of 36.8 g (80.9 mmol) of 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(3-oxopropyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide, from Step F above, in 100 ml of tetrahydrofuran was added over a period of thirty minutes. The resulting solution was stirred for 30 minutes at -78° C. and then warmed to 0° C. where it was held for an additional 60 minutes.</p>
    <p>The mixture was then acidified by the dropwise addition of 300 ml of ice-cold 3M hydrochloric acid, diluted with ether, washed successively with water and brine, dried over anhydrous magnesium sulfate, and concentrated. Flash chromatography of the residue yielded 37.9 g of 2-(4-fluorophenyl)-δ-hydroxy-5-(1-methylethyl)-β-oxo-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, methyl ester.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of the product exhibited signals at 1.50 (doublet, 6H, J=7 Hz); 1.8 (multiplet, 2H); 2.45 (doublet, 2H, J=7 Hz); 2.8 (broad, 1H); 3.33 (singlet, 2H); 3.5 (multiplet, 1H); 3.67 (singlet, 3H); 3.8-4.0 (multiplet, 2H); and 6.8-7.3 (multiplet, 14H) parts per million downfield from tetramethylsilane.</p>
    <p>Step H. Preparation of R*,R*-2-(4-fluorophenyl-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid and trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide</p>
    <p>Air (60 ml) was bubbled via a syringe through a solution of 2-(4-fluorophenyl)-δ-hydroxy-5-(1-methylethyl)-β-oxo-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, methyl ester (48 g, 84.1 mmol) and 92.5 ml of 1M tributylborane in 100 ml of anhydrous tetrahydrofuran. The mixture was stirred overnight at room temperature and then cooled to -78° C. Sodium borohydride (3.85 g, 101.8 mmol) was added to the cooled mixture in one portion. The mixture was allowed to warm slowly to 0° C. over a period of three hours, during which there was vigorous gas evolution.</p>
    <p>The dry ice-acetone bath applied to the reaction vessel was replaced by an ice bath and 18.3 ml of glacial acetic acid were added dropwise, followed by 204 ml of 3M aqueous sodium hydroxide solution and 30.5 ml of 30% aqueous hydrogen peroxide solution.</p>
    <p>The mixture was vigorously stirred while being allowed to warm to room temperature overnight. The mixture was then partitioned between diethyl ether and water and the aqueous layer was separated, acidified, and extracted with ethyl acetate.</p>
    <p>The ethyl acetate extract was washed with brine, dried, and evaporated to yield crude R*,R*-2-(4-fluorophenyl-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid which was used without further purification.</p>
    <p>The crude acid was taken up in toluene and lactonized by heating under reflux for six hours. This mixture was chromatographed to provide 30 g of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide as a foamy solid, mp 90°-97° C.</p>
    <p>Analyzed for C<sub>33</sub> H<sub>33</sub> FN<sub>2</sub> O<sub>4</sub> : Calc.: C, 73.31%; H, 6.15%; N, 5.18%; Found: C, 73.46%; H, 6.31%; N, 5.28%.</p>
    <p>This material was found by HPLC analysis to comprise a 9:1 molar ratio of the cis- and trans-isomeric forms of the product. Recrystallization from toluene-ethyl acetate yield the essentially pure trans-form, mp 148°-149° C.</p>
    <heading>EXAMPLE 2</heading> <heading>Preparation of R*,R*-2-(4-fluoro-phenyl-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, sodium salt</heading> <p>A mixture of trans-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide (10 g, 18.5 mmol) and 0.74 g (18.5 mmol) of sodium hydroxide in 90 ml of a 1:2 mixture of tetrahydrofuran-water was cooled to 0° C. This mixture was allowed to warm slowly to 25° C., after which time it was concentrated and the residual solid dried under vacuum.</p>
    <p>The infrared spectrum of the product exhibited principal absorption peaks at 3400, 1651, 1598, 1565, 1511, 1438, 1412, 1316, 1224, 1159, 844, 754, and 702 reciprocal centimeters.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of a hexadeutero dimethylsulfoxide solution of the product exhibited signals at 1.34 (doublet, J=7 Hz, 6H); 1.5 (multiplet, 4H); 1.80 (doublet of doublets, J=15, 8 Hz, 1H); 1.99 (doublet of doublets, J=15, 4 Hz, 1H); 3-4 (multiplet, 8H); 6.9-7.3 (multiplet, 12H); 7.50 (doublet, J=8 Hz, 2H); and 9.85 (singlet, 1H) parts per million downfield from tetramethylsilane.</p>
    <heading>EXAMPLES 3 AND 4</heading> <heading>Preparation of trans-2-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-5-(trifluoromethyl)-pyrrole-3-carboxamide and trans-5-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-(trifluoromethyl)pyrrole-3-carboxamide</heading> <p>Step A. Preparation of α-[[2-(1,3-dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid.</p>
    <p>α-[[2-(1,3-Dioxolan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid, ethyl ester (36.5 g, 122.8 mmol, prepared as described above in Example 1, Step A) was dissolved in 1500 ml of a 5:1 mixture of methanol-water together with 7.6 g of sodium hydroxide. This mixture was heated under reflux for a period of two and one-half hours after which time the solvents were removed under vacuum.</p>
    <p>The solid residue was taken up in 325 ml of water and a mixture of 14 ml of glacial acetic in 28 ml of water was added with stirring. After stirring for a time, an additional 3 ml of glacial acetic acid were added and the mixture was chilled for 75 minutes. The solids were collected by filtration, washed with water and then ethyl acetate and dried to yield α-[[2-(1,3-dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid, mp 218°-220° C.</p>
    <p>Step B. Preparation of a mixture of 5-(4-fluorophenyl)-1-(3-oxopropyl)-N,4-diphenyl-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide and 2-(4-fluorophenyl)-1-(3-oxopropyl)-N,4-diphenyl-5-(trifluoromethyl)-1H-pyrrole-3-carboxamide</p>
    <p>α-[[2-(1,3-Dioxalan-2-yl)ethyl]amino]-4-fluorobenzeneacetic acid (6.06 g, 22.5 mmol) was dissolved in 45 ml of trifluoroacetic anhydride and 7.47 g (33.8 mmol) of N,3-diphenyl-2-propynamide (prepared as described above in Example 1, Step D) was added. The resulting mixture was heated under reflux for a period of five and one-half hours. The mixture was then cooled, and 1.74 ml of trifluoroacetic acid were added and the mixture was stirred overnight.</p>
    <p>The excess trifluoroacetic anhydride was removed under vacuum, and water was added, followed by sufficient acetone to give a homogenous solution. This solution was stirred at room temperature for three hours. The mixture was seeded with N,3-diphenyl-2-propynamide, and a precipitate formed. After three hours, this precipitate was removed by filtration.</p>
    <p>The acetone was removed from the filtrate under vacuum and the solid residue was taken up in ether, washed successively with two portions of water, two portions of sodium bicarbonate solution, and two portions of brine and dried over anhydrous magnesium sulfate. The ether was removed under vacuum to yield a crude mixture of the two title compounds.</p>
    <p>This mixture was separated by column chromatography on 600 g of silica gel, eluting with a 4:1 mixture of hexane-ethyl acetate.</p>
    <p>The first fraction eluted was 5-(4-fluorophenyl)-1-(3-oxopropyl)-N,4-diphenyl-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of a deuterochloroform solution of this material exhibited signals at 2.73 (triplet, J=7 Hz, 2H); 4.21 (triplet, J=7 Hz, 2H); 6.7-7.3 (multiplet, 5H); 7.40 (singlet, 5H), and 9.43 (singlet, 1H) parts per million downfield from tetramethylsilane.</p>
    <p>The second compound eluted from the column was 2-(4-fluorophenyl)-1-(3-oxopropyl)-N,4-diphenyl-5-(trifluoromethyl)-1H-pyrrole-3-carboxamide.</p>
    <p>The 90 MHz proton magnetic resonance spectrum of a deuterochloroform solution of this material exhibited signals at 2.67 (triplet, J=7 Hz, 2H); 4.25 (triplet, J=7 Hz, 2H); 7.0-7.3 (multiplet, 14H); and 9.43 (singlet, 1H) parts per million downfield from tetramethylsilane.</p>
    <p>Step C. Preparation of trans-2-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-5-(trifluoromethyl)-pyrrole-3-carboxamide and trans-5-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-(trifluoromethyl)-pyrrole-3-carboxamide</p>
    <p>Employing the general methods detailed in Example 1, Steps G and H, the title compounds were prepared from the aldehyde compounds of this example, Step B.</p>
    <p>The elemental analyses of the two title compounds were:</p>
    <p>For trans-5-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-2-(trifluoromethyl)-pyrrole-3-carboxamide:</p>
    <p>Analyzed for C<sub>31</sub> H<sub>26</sub> N<sub>2</sub> O<sub>4</sub> : Calc.: C, 65.72%; H, 4.63%; N, 4.94%; Found: C, 65.82%; H, 4.91%; N, 4.69%.</p>
    <p>The trans-2-(4-fluorophenyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-5-(trifluoromethyl)-pyrrole-3-carboxamide was found, upon recrystallization from toluene to contain 0.25 mols of toluene as solvent of crystallization, mp 106°-111° C.</p>
    <p>Analyzed for C<sub>31</sub> H<sub>26</sub> N<sub>2</sub> O<sub>4</sub>.0.25C<sub>7</sub> H<sub>8</sub> : Calc.: C, 66.72%; H, 4.79%; N, 4.72%; Found: C, 66.81%; H, 4.86%; N, 4.60%.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3983140">US3983140</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 12, 1975</td><td class="patent-data-table-td patent-date-value">Sep 28, 1976</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">Physiologically active substances</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4049495">US4049495</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 4, 1975</td><td class="patent-data-table-td patent-date-value">Sep 20, 1977</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">Physiologically active substances and fermentative process for producing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4137322">US4137322</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 31, 1977</td><td class="patent-data-table-td patent-date-value">Jan 30, 1979</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4198425">US4198425</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 8, 1978</td><td class="patent-data-table-td patent-date-value">Apr 15, 1980</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">Antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4255444">US4255444</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 26, 1979</td><td class="patent-data-table-td patent-date-value">Mar 10, 1981</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">4-Hydroxy-2-pyrone derivatives having antihyperlipaemic activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4262013">US4262013</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 3, 1979</td><td class="patent-data-table-td patent-date-value">Apr 14, 1981</td><td class="patent-data-table-td ">Sankyo Company Limited</td><td class="patent-data-table-td ">Antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4375475">US4375475</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 11, 1981</td><td class="patent-data-table-td patent-date-value">Mar 1, 1983</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Substituted pyranone inhibitors of cholesterol synthesis</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Brown, et al.; J. Chem. Soc. Perkin I, (1976), pp. 1165 1170.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brown, et al.; J. Chem. Soc. Perkin I, (1976), pp. 1165-1170.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Brown, et al.; New England Jour. of Med., vol. 305, No. 9, pp. 515 517, (1981).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brown, et al.; New England Jour. of Med., vol. 305, No. 9, pp. 515-517, (1981).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hulcher; Arch. Biochem. Biophys., vol. 146, pp. 422 427, (1971).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hulcher; Arch. Biochem. Biophys., vol. 146, pp. 422-427, (1971).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of the Americas Medical Assoc.; (1984), vol. 251, pp. 351 364, 365 374.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of the Americas Medical Assoc.; (1984), vol. 251, pp. 351-364, 365-374.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Singer, et al.; Proc. Soc. Exper. Biol. Med.; vol. 102, pp. 370 373, (1959).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Singer, et al.; Proc. Soc. Exper. Biol. Med.; vol. 102, pp. 370-373, (1959).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4761419">US4761419</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 7, 1987</td><td class="patent-data-table-td patent-date-value">Aug 2, 1988</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Antilipemic</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4851427">US4851427</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 1986</td><td class="patent-data-table-td patent-date-value">Jul 25, 1989</td><td class="patent-data-table-td ">Sandoz Pharm. Corp.</td><td class="patent-data-table-td ">Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4868185">US4868185</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 10, 1987</td><td class="patent-data-table-td patent-date-value">Sep 19, 1989</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Hypolipidemic, anticholesterol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4892884">US4892884</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 5, 1988</td><td class="patent-data-table-td patent-date-value">Jan 9, 1990</td><td class="patent-data-table-td ">Rorer Pharmaceutical Corporation</td><td class="patent-data-table-td ">Anticholesterol, antilipemic</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4897490">US4897490</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 18, 1988</td><td class="patent-data-table-td patent-date-value">Jan 30, 1990</td><td class="patent-data-table-td ">Bristol-Meyers Company</td><td class="patent-data-table-td ">Antihypercholesterolemic tetrazole compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4898949">US4898949</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 18, 1988</td><td class="patent-data-table-td patent-date-value">Feb 6, 1990</td><td class="patent-data-table-td ">Bristol-Myers Company</td><td class="patent-data-table-td ">Treatment of hyperlipemia, atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4900754">US4900754</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 27, 1989</td><td class="patent-data-table-td patent-date-value">Feb 13, 1990</td><td class="patent-data-table-td ">Rorer Pharmaceutical Corp.</td><td class="patent-data-table-td ">HMG-COA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4904691">US4904691</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 10, 1989</td><td class="patent-data-table-td patent-date-value">Feb 27, 1990</td><td class="patent-data-table-td ">Rorer Pharmaceutical Corporation</td><td class="patent-data-table-td ">Novel HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4904692">US4904692</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 12, 1988</td><td class="patent-data-table-td patent-date-value">Feb 27, 1990</td><td class="patent-data-table-td ">Rorer Pharmaceutical Corporation</td><td class="patent-data-table-td ">Novel HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4906624">US4906624</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 2, 1988</td><td class="patent-data-table-td patent-date-value">Mar 6, 1990</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4906657">US4906657</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 21, 1988</td><td class="patent-data-table-td patent-date-value">Mar 6, 1990</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4939143">US4939143</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 25, 1989</td><td class="patent-data-table-td patent-date-value">Jul 3, 1990</td><td class="patent-data-table-td ">Rorer Pharmaceutical Corporation</td><td class="patent-data-table-td ">Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4946963">US4946963</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 31, 1988</td><td class="patent-data-table-td patent-date-value">Aug 7, 1990</td><td class="patent-data-table-td ">The University Of North Carolina At Chapel Hill</td><td class="patent-data-table-td ">Compounds for the control of hyperlipidemia using N-substituted isoxazolidine-3,5-diones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4957940">US4957940</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 21, 1989</td><td class="patent-data-table-td patent-date-value">Sep 18, 1990</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Enzyme inhibitors, antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4992429">US4992429</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 24, 1989</td><td class="patent-data-table-td patent-date-value">Feb 12, 1991</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Novel HMG-COA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4992462">US4992462</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 7, 1988</td><td class="patent-data-table-td patent-date-value">Feb 12, 1991</td><td class="patent-data-table-td ">Bayer Aktiengesellschaft</td><td class="patent-data-table-td ">Inhibitor of HMG-CoA reductase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4996234">US4996234</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 5, 1989</td><td class="patent-data-table-td patent-date-value">Feb 26, 1991</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4997837">US4997837</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 6, 1989</td><td class="patent-data-table-td patent-date-value">Mar 5, 1991</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4999366">US4999366</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 12, 1990</td><td class="patent-data-table-td patent-date-value">Mar 12, 1991</td><td class="patent-data-table-td ">The North Carolina Central Univ.</td><td class="patent-data-table-td ">Isoxazolidine-3,5-diones, pharmaceutical compositions and method of treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5001128">US5001128</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 15, 1989</td><td class="patent-data-table-td patent-date-value">Mar 19, 1991</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">HMG-COA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5001144">US5001144</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 17, 1990</td><td class="patent-data-table-td patent-date-value">Mar 19, 1991</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5003080">US5003080</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 1, 1989</td><td class="patent-data-table-td patent-date-value">Mar 26, 1991</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5010205">US5010205</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 28, 1989</td><td class="patent-data-table-td patent-date-value">Apr 23, 1991</td><td class="patent-data-table-td ">Bristol-Myers Company</td><td class="patent-data-table-td ">Antihypercholesterolemic tetrazol-1-yl intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5026708">US5026708</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 12, 1988</td><td class="patent-data-table-td patent-date-value">Jun 25, 1991</td><td class="patent-data-table-td ">Nissan Chemical Industries Ltd.</td><td class="patent-data-table-td ">Antilipemic, antilipolytic, anticholesterol agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5034409">US5034409</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 1990</td><td class="patent-data-table-td patent-date-value">Jul 23, 1991</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Pyrrole carboxylic acids and esters for blood platelet aggregation inhibition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5055484">US5055484</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 8, 1988</td><td class="patent-data-table-td patent-date-value">Oct 8, 1991</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">7(1h-pyrrol-3-yl)-substituted 3,5-dihydroxyhept-6-enoic acids, 7-(1h-pyrrol-3-yl)-substituted 3,5-dihyroxyhept-anoic acids, their corresponding delta-lactones and salts, their use as medicaments and pharmaceutical products and intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5097045">US5097045</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 9, 1990</td><td class="patent-data-table-td patent-date-value">Mar 17, 1992</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5103024">US5103024</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 17, 1990</td><td class="patent-data-table-td patent-date-value">Apr 7, 1992</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5124482">US5124482</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 14, 1991</td><td class="patent-data-table-td patent-date-value">Jun 23, 1992</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5132312">US5132312</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 27, 1990</td><td class="patent-data-table-td patent-date-value">Jul 21, 1992</td><td class="patent-data-table-td ">Rhone-Poulenc Rorer Pharmaceuticals Inc.</td><td class="patent-data-table-td ">3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors as anticholesterol agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5149837">US5149837</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 12, 1992</td><td class="patent-data-table-td patent-date-value">Sep 22, 1992</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">1,3-Dioxane intermediate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5155251">US5155251</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 11, 1991</td><td class="patent-data-table-td patent-date-value">Oct 13, 1992</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5173495">US5173495</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 8, 1990</td><td class="patent-data-table-td patent-date-value">Dec 22, 1992</td><td class="patent-data-table-td ">Bayer Aktiengesellschaft</td><td class="patent-data-table-td ">7-[(2,6-dialkyl-4-furyl or thienyl-pyridyl)]-3,5-di-(dihydroxy-6-enoates) useful for treating circulatory diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5204351">US5204351</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 4, 1989</td><td class="patent-data-table-td patent-date-value">Apr 20, 1993</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Antiarteriosclerosis, anticholesterol agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5216174">US5216174</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 1, 1992</td><td class="patent-data-table-td patent-date-value">Jun 1, 1993</td><td class="patent-data-table-td ">Warner-Lambert Co.</td><td class="patent-data-table-td ">Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5248793">US5248793</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 21, 1992</td><td class="patent-data-table-td patent-date-value">Sep 28, 1993</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5273995">US5273995</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 26, 1991</td><td class="patent-data-table-td patent-date-value">Dec 28, 1993</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">[R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5280126">US5280126</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 6, 1993</td><td class="patent-data-table-td patent-date-value">Jan 18, 1994</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5288928">US5288928</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 20, 1992</td><td class="patent-data-table-td patent-date-value">Feb 22, 1994</td><td class="patent-data-table-td ">Ciba-Geigy Corporation</td><td class="patent-data-table-td ">Asymmetrical hydrogenation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5298627">US5298627</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 3, 1993</td><td class="patent-data-table-td patent-date-value">Mar 29, 1994</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Anticholesterol, hypolipidemic agents, enzyme inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5342952">US5342952</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 12, 1993</td><td class="patent-data-table-td patent-date-value">Aug 30, 1994</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5385929">US5385929</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 4, 1994</td><td class="patent-data-table-td patent-date-value">Jan 31, 1995</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">[(Hydroxyphenylamino) carbonyl] pyrroles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5397792">US5397792</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 16, 1994</td><td class="patent-data-table-td patent-date-value">Mar 14, 1995</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5446054">US5446054</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 14, 1994</td><td class="patent-data-table-td patent-date-value">Aug 29, 1995</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5470981">US5470981</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 18, 1995</td><td class="patent-data-table-td patent-date-value">Nov 28, 1995</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5470982">US5470982</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 24, 1992</td><td class="patent-data-table-td patent-date-value">Nov 28, 1995</td><td class="patent-data-table-td ">Bayer Aktiengesellschaft</td><td class="patent-data-table-td ">Disubstituted pyridines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5489690">US5489690</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 1995</td><td class="patent-data-table-td patent-date-value">Feb 6, 1996</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for trans-6[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5489691">US5489691</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 1995</td><td class="patent-data-table-td patent-date-value">Feb 6, 1996</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Cyclization; decyclization; hydrolysis; neutralization; salt formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5502057">US5502057</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 14, 1993</td><td class="patent-data-table-td patent-date-value">Mar 26, 1996</td><td class="patent-data-table-td ">Bayer Aktiengesellschaft</td><td class="patent-data-table-td ">Polysubstituted pyridines useful for treating lipoproteinanaemia and arteriosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5510488">US5510488</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 1995</td><td class="patent-data-table-td patent-date-value">Apr 23, 1996</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Chemical intermeidates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5686104">US5686104</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 20, 1994</td><td class="patent-data-table-td patent-date-value">Nov 11, 1997</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Stable oral CI-981 formulation and process of preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5919464">US5919464</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 23, 1993</td><td class="patent-data-table-td patent-date-value">Jul 6, 1999</td><td class="patent-data-table-td ">University Of New Mexico</td><td class="patent-data-table-td ">Controlling cell differentiation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5958966">US5958966</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 5, 1995</td><td class="patent-data-table-td patent-date-value">Sep 28, 1999</td><td class="patent-data-table-td ">University Of New Mexico</td><td class="patent-data-table-td ">Treatment of aberrant cellular states with biomodulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6087511">US6087511</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 16, 1996</td><td class="patent-data-table-td patent-date-value">Jul 11, 2000</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6126971">US6126971</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 2, 1997</td><td class="patent-data-table-td patent-date-value">Oct 3, 2000</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Stable oral CI-981 formulation and process for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6177121">US6177121</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 1998</td><td class="patent-data-table-td patent-date-value">Jan 23, 2001</td><td class="patent-data-table-td ">Purdue Research Foundation</td><td class="patent-data-table-td ">Composition and method for producing low cholesterol eggs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6262092">US6262092</a></td><td class="patent-data-table-td patent-date-value">May 24, 2000</td><td class="patent-data-table-td patent-date-value">Jul 17, 2001</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Mutual salt of amlodipine and atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6274740">US6274740</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">Aug 14, 2001</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethy)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6455574">US6455574</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 2000</td><td class="patent-data-table-td patent-date-value">Sep 24, 2002</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Administering a combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof for treatment of combined hypertension and hyperlipidemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6476235">US6476235</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 17, 2001</td><td class="patent-data-table-td patent-date-value">Nov 5, 2002</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6486182">US6486182</a></td><td class="patent-data-table-td patent-date-value">May 24, 2000</td><td class="patent-data-table-td patent-date-value">Nov 26, 2002</td><td class="patent-data-table-td ">Pfizer Inc</td><td class="patent-data-table-td ">Mutual prodrugs of amlodipine and atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6528661">US6528661</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2001</td><td class="patent-data-table-td patent-date-value">Mar 4, 2003</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Providing atorvastatin ester derivative; converting the atorvastatin ester derivative to atorvastatin hemi-calcium with calcium hydroxide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6545153">US6545153</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2002</td><td class="patent-data-table-td patent-date-value">Apr 8, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Anticholesterol agents; antilipemic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6569461">US6569461</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2000</td><td class="patent-data-table-td patent-date-value">May 27, 2003</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6600051">US6600051</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2002</td><td class="patent-data-table-td patent-date-value">Jul 29, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605636">US6605636</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2001</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Atorvastatin hemi-calcium form VII</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605728">US6605728</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2002</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Starting from atorvastatin lactone, where continuous agitation at a very low speed provides optimum drying conditions for avoiding clod formation and particle attrition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6605729">US6605729</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2002</td><td class="patent-data-table-td patent-date-value">Aug 12, 2003</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6730797">US6730797</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 2003</td><td class="patent-data-table-td patent-date-value">May 4, 2004</td><td class="patent-data-table-td ">Pfizer Science And Technology Ireland Limited</td><td class="patent-data-table-td ">Process for producing crystalline atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6747048">US6747048</a></td><td class="patent-data-table-td patent-date-value">May 7, 2003</td><td class="patent-data-table-td patent-date-value">Jun 8, 2004</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Pyridine-based thyroid receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6750353">US6750353</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2002</td><td class="patent-data-table-td patent-date-value">Jun 15, 2004</td><td class="patent-data-table-td ">Lek Pharmaceutical &amp; Chemical Co. D.D.</td><td class="patent-data-table-td ">Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6774112">US6774112</a></td><td class="patent-data-table-td patent-date-value">Apr 8, 2002</td><td class="patent-data-table-td patent-date-value">Aug 10, 2004</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Antidiabetic agents; cardiovascular disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6777552">US6777552</a></td><td class="patent-data-table-td patent-date-value">Aug 16, 2002</td><td class="patent-data-table-td patent-date-value">Aug 17, 2004</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">From an ester derivative or protected ester derivative of the statin by using calcium hydroxide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6777560">US6777560</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 2003</td><td class="patent-data-table-td patent-date-value">Aug 17, 2004</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6806381">US6806381</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 2002</td><td class="patent-data-table-td patent-date-value">Oct 19, 2004</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Process for the preparation of aniline-derived thyroid receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6831102">US6831102</a></td><td class="patent-data-table-td patent-date-value">Dec 6, 2002</td><td class="patent-data-table-td patent-date-value">Dec 14, 2004</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">For treating or delaying progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, cardiac arrhythmia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6841554">US6841554</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2001</td><td class="patent-data-table-td patent-date-value">Jan 11, 2005</td><td class="patent-data-table-td ">Astrazeneca Ab</td><td class="patent-data-table-td ">Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6867306">US6867306</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2001</td><td class="patent-data-table-td patent-date-value">Mar 15, 2005</td><td class="patent-data-table-td ">Biocon Limited</td><td class="patent-data-table-td ">Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6933393">US6933393</a></td><td class="patent-data-table-td patent-date-value">Jan 21, 2003</td><td class="patent-data-table-td patent-date-value">Aug 23, 2005</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Reacting methyl cyanoacetate with morphiline to form 3-morpholin-4-yl-3-oxo- propionitrile; forming salt; reacting with phenylacetic acid and 2-(2-(4-fluorophenyl)-2-oxo-1-phenyl-ethyl)-4-</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6951844">US6951844</a></td><td class="patent-data-table-td patent-date-value">Sep 21, 2004</td><td class="patent-data-table-td patent-date-value">Oct 4, 2005</td><td class="patent-data-table-td ">Bristol Myers Squibb Company</td><td class="patent-data-table-td ">substituted 5-phenyl-2-naphthols; metabolic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6984645">US6984645</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2002</td><td class="patent-data-table-td patent-date-value">Jan 10, 2006</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Aryl carboxylic acids and tetrazoles for treating diabetes, especially type II diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6992194">US6992194</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2004</td><td class="patent-data-table-td patent-date-value">Jan 31, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6995180">US6995180</a></td><td class="patent-data-table-td patent-date-value">Oct 21, 2003</td><td class="patent-data-table-td patent-date-value">Feb 7, 2006</td><td class="patent-data-table-td ">Bristol Myers Squibb Company</td><td class="patent-data-table-td ">for the treatment of diabetes, hyperglycemia, hypoglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, eating disorders, and nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6995183">US6995183</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2004</td><td class="patent-data-table-td patent-date-value">Feb 7, 2006</td><td class="patent-data-table-td ">Bristol Myers Squibb Company</td><td class="patent-data-table-td ">Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7057046">US7057046</a></td><td class="patent-data-table-td patent-date-value">May 19, 2003</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Lactam glycogen phosphorylase inhibitors and method of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7074940">US7074940</a></td><td class="patent-data-table-td patent-date-value">Oct 3, 2003</td><td class="patent-data-table-td patent-date-value">Jul 11, 2006</td><td class="patent-data-table-td ">Lek Pharmaceutical &amp; Chemical Co. D.D.</td><td class="patent-data-table-td ">Preparation of pharmaceutically acceptable atorvastatin salts in non-crystalline forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7078430">US7078430</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 5, 2003</td><td class="patent-data-table-td patent-date-value">Jul 18, 2006</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">3-carbamoyl-pyran that is n-derivatized by dihydroxyheptanoic acid or 6-ethyl-4-hydroxy-pyran-2-one; anticholesterol agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7084282">US7084282</a></td><td class="patent-data-table-td patent-date-value">Jun 8, 2004</td><td class="patent-data-table-td patent-date-value">Aug 1, 2006</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Process for preparing 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7098235">US7098235</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2003</td><td class="patent-data-table-td patent-date-value">Aug 29, 2006</td><td class="patent-data-table-td ">Bristol-Myers Squibb Co.</td><td class="patent-data-table-td ">Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7112604">US7112604</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2005</td><td class="patent-data-table-td patent-date-value">Sep 26, 2006</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Process for the preparation of Atorvastatin and intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7122681">US7122681</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Oct 17, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Displacement of solvent by vapor diffusion of water</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7129352">US7129352</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2004</td><td class="patent-data-table-td patent-date-value">Oct 31, 2006</td><td class="patent-data-table-td ">Astrazeneca Ab</td><td class="patent-data-table-td ">Reacting with sodium hydroxide then calcium chloride to form calcium salt derivative; 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7144916">US7144916</a></td><td class="patent-data-table-td patent-date-value">Nov 19, 2004</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7145040">US7145040</a></td><td class="patent-data-table-td patent-date-value">Jun 30, 2005</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Bristol-Myers Squibb Co.</td><td class="patent-data-table-td ">Process for the preparation of amino acids useful in the preparation of peptide receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7151183">US7151183</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Dec 19, 2006</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Processes for preparing amorphous atorvastatin hemi-calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7161012">US7161012</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Processes for preparing amorphous atorvastatin hemi-calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7183408">US7183408</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 2005</td><td class="patent-data-table-td patent-date-value">Feb 27, 2007</td><td class="patent-data-table-td ">Warner-Lambert Company, Llc</td><td class="patent-data-table-td ">calcium atorvastatin (Lipitor) intermediate; from claimed intermediate 5-(4-fluorophenyl)-2-isopropyl-1-(3-morpholin-4-yl-3-oxo-propyl)-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide; via diol esters from the 1,3,5-tricarbonyl precursors in a stereoselective ruthenium-catalyzed hydrogenation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7189861">US7189861</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Mar 13, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Ball milling any crystalline form of atorvastatin hemi-calcium to obtain a polymorphic crystal structure with small particle size distribution; monodispersity; improved physical properties of filtration/drying characteristics, flowability, vapor impermeability, solubility; drug-releasing design</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7208608">US7208608</a></td><td class="patent-data-table-td patent-date-value">Jan 30, 2003</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Zentiva A. S.</td><td class="patent-data-table-td ">Conversion of (3R,5R) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid or its salt containing alkali metal or ammonium cation, by treatment of the calcium salt to the hemi-calcium salt, followed by precipitation with C5 C12 hydrocarbon or dialkyl ether</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7220859">US7220859</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td patent-date-value">May 22, 2007</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">For use in therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7238670">US7238670</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2002</td><td class="patent-data-table-td patent-date-value">Jul 3, 2007</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7238671">US7238671</a></td><td class="patent-data-table-td patent-date-value">Apr 21, 2003</td><td class="patent-data-table-td patent-date-value">Jul 3, 2007</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">coadministration with and at least one therapeutic agent selected from the group consisting of an antidiabetic agent, an anti-obesity agent, a anti-hypertensive agent, an anti-atherosclerotic agent and a lipid-lowering agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7238702">US7238702</a></td><td class="patent-data-table-td patent-date-value">Feb 9, 2006</td><td class="patent-data-table-td patent-date-value">Jul 3, 2007</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Dihydroquinazolinones as 5HT modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7250444">US7250444</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 2004</td><td class="patent-data-table-td patent-date-value">Jul 31, 2007</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Pyrrole-based HMG-CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7256212">US7256212</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Aug 14, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7276536">US7276536</a></td><td class="patent-data-table-td patent-date-value">Mar 17, 2004</td><td class="patent-data-table-td patent-date-value">Oct 2, 2007</td><td class="patent-data-table-td ">Japan Tobacco Inc.</td><td class="patent-data-table-td ">By administering with food; drug is dalcetrapib; use in treatment of cardiovascular disease, coronary heart disease, coronary artery disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7314882">US7314882</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td patent-date-value">Jan 1, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Benzyl 2-oxo-6-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-3-ylcarbamate; CB-1 antagonist; regulating appetitive behavior</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7317012">US7317012</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Jan 8, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Bicyclic heterocycles as cannabinoind-1 receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7317109">US7317109</a></td><td class="patent-data-table-td patent-date-value">May 1, 2006</td><td class="patent-data-table-td patent-date-value">Jan 8, 2008</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">(2R)-1-{2-[(3S)-Pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; antidiabetic</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7323490">US7323490</a></td><td class="patent-data-table-td patent-date-value">May 18, 2004</td><td class="patent-data-table-td patent-date-value">Jan 29, 2008</td><td class="patent-data-table-td ">Ambit Biosciences Corporation</td><td class="patent-data-table-td ">Pyrrole compounds and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7342120">US7342120</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Mar 11, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries, Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7342127">US7342127</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 2004</td><td class="patent-data-table-td patent-date-value">Mar 11, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Substituted anilide ligands for the thyroid receptor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361766">US7361766</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">N-(1-Benzyl-2-oxo-1,2,3,4-tetrahydro-1,6-naphthyridin-3-yl)-benzenesulfonamide; CB-1 antagonist; regulating appetitive behavior</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7361771">US7361771</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7368458">US7368458</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td patent-date-value">May 6, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">N-(1-Benzyl-2-oxo-6-phenyl-1,2,3,4-tetrahydro-1,8-naphthyridin-3-yl)benzenesulfonamide; antagonists; regulation of appetite; obesity; smoking cessation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7368469">US7368469</a></td><td class="patent-data-table-td patent-date-value">Jul 21, 2006</td><td class="patent-data-table-td patent-date-value">May 6, 2008</td><td class="patent-data-table-td ">Sanofi-Aventis Deutschland Gmbh</td><td class="patent-data-table-td ">Prophylaxis of stroke, cardiovascular death or myocardial infarction by administering an angiotenzin converting enzyme inhibitor: ramipril, ramiprilat or their salts, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7371855">US7371855</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">May 13, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7399773">US7399773</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">Jul 15, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Intermediates in the synthesis of atorvastatin calcium (Lipitor (reg)), 5-(4-fluorophenyl)-2-isopropyl-1-(4-(morpholinocarbonylmethylcarbonyl)-2-hydroxybutyl)-4-phenyl-3-(N-phenylcarbamoyl)-1H-pyrrole for example</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7411075">US7411075</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">Aug 12, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7417028">US7417028</a></td><td class="patent-data-table-td patent-date-value">Jun 30, 2005</td><td class="patent-data-table-td patent-date-value">Aug 26, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7425550">US7425550</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2006</td><td class="patent-data-table-td patent-date-value">Sep 16, 2008</td><td class="patent-data-table-td ">Bristol-Meyers Squibb Company</td><td class="patent-data-table-td ">Lactam glycogen phosphorylase inhibitors and method of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7429613">US7429613</a></td><td class="patent-data-table-td patent-date-value">Jul 17, 2006</td><td class="patent-data-table-td patent-date-value">Sep 30, 2008</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Preparing 5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3hydroxyl-1-pentanoic acid 7 by reacting aldehyde with 2-hydroxy-1,2,2-triphenylethyl acetate and a chelating cosolvent; hydrolysis; carboxylation by reaction with base; salt formation, purification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7446121">US7446121</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Nov 4, 2008</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Pyrazole-based HMG CoA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452892">US7452892</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">2-substituted 7-aryl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; mitogen-activated protein kinase inhibitor; physiological and psychotropic effects including regulation of appetite, immunosuppression, analgesia, inflammation, emesis, anti-nocioception, sedation, and intraocular pressure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7456297">US7456297</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2005</td><td class="patent-data-table-td patent-date-value">Nov 25, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">crystalline polymorphic dosage forms of anticholesterol agents; statins; small particle size distribution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7459474">US7459474</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 2004</td><td class="patent-data-table-td patent-date-value">Dec 2, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">1,2,4 triazole nonsteroidal derivatives; diseases associated with nuclear factor kappa beta induced transcription</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7468444">US7468444</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Dec 23, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystalline polymorphic dosage forms of anticholesterol agents; statins; suspending atorvastatin hemi-calcium in water for 16 hours convert the atorvastatin hemi-calcium into Form I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7482367">US7482367</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2006</td><td class="patent-data-table-td patent-date-value">Jan 27, 2009</td><td class="patent-data-table-td ">Novartis Vaccines And Diagnostics, Inc.</td><td class="patent-data-table-td ">Substituted benzimidazoles and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7488750">US7488750</a></td><td class="patent-data-table-td patent-date-value">Oct 24, 2005</td><td class="patent-data-table-td patent-date-value">Feb 10, 2009</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7501450">US7501450</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Mar 10, 2009</td><td class="patent-data-table-td ">Teva Pharaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7517991">US7517991</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2005</td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">metabolic and eating disorders, improvement of cognitive function, substance abuse disorders, cognitive disorders, autoimmune glomerulonephritis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7521557">US7521557</a></td><td class="patent-data-table-td patent-date-value">May 9, 2006</td><td class="patent-data-table-td patent-date-value">Apr 21, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7534763">US7534763</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2006</td><td class="patent-data-table-td patent-date-value">May 19, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Sustained release GLP-1 receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7534810">US7534810</a></td><td class="patent-data-table-td patent-date-value">Jul 9, 2008</td><td class="patent-data-table-td patent-date-value">May 19, 2009</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553836">US7553836</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2007</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">7-(4-Chlorophenyl)-2-(3-methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one trifluoroacetic acid salt; obesity; antidiabetic agents; antidepressants; anxiolytic agents; combination with antipsychotic drugs enhanced therayp for schizophrenic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553854">US7553854</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2007</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">Novartis Vaccines And Diagnostics, Inc.</td><td class="patent-data-table-td ">6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7557143">US7557143</a></td><td class="patent-data-table-td patent-date-value">Apr 15, 2004</td><td class="patent-data-table-td patent-date-value">Jul 7, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Such as 3,5-Dibromo-4-(4-hydroxy-3-phenethylcarbamoyl-phenoxy)-phenyl acetic acid; metabolism regulation agents; avoiding cardiovascular and other toxicities of hormones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7563911">US7563911</a></td><td class="patent-data-table-td patent-date-value">Aug 31, 2001</td><td class="patent-data-table-td patent-date-value">Jul 21, 2009</td><td class="patent-data-table-td ">Morepen Laboratories Ltd.</td><td class="patent-data-table-td ">Process for the preparation of amorphous atorvastin calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7572808">US7572808</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Aug 11, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">2-substituted 7-aryl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; mitogen-activated protein kinase inhibitor; physiological and psychotropic effects including regulation of appetite, immunosuppression, analgesia, inflammation, emesis, anti-nocioception, sedation, and intraocular pressure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7576121">US7576121</a></td><td class="patent-data-table-td patent-date-value">May 1, 2006</td><td class="patent-data-table-td patent-date-value">Aug 18, 2009</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Antidiabetic agenst</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7589088">US7589088</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2005</td><td class="patent-data-table-td patent-date-value">Sep 15, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7589193">US7589193</a></td><td class="patent-data-table-td patent-date-value">Sep 23, 2005</td><td class="patent-data-table-td patent-date-value">Sep 15, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">C-aryl glucoside SGLT2 inhibitors and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7615647">US7615647</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2005</td><td class="patent-data-table-td patent-date-value">Nov 10, 2009</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Process for producing atorvastatin hemicalcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7629342">US7629342</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 8, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7632837">US7632837</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 15, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">6-(2-Chlorophenyl)-7-(4-chlorophenyl)-N-cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazin-3-amine; drug abuse, drug dependency; smoking cigarettes; appetite suppressants; antilipemic agents; anticholesterol agents; increasing high density lipoproteins;hypotensive agents; antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7635699">US7635699</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2005</td><td class="patent-data-table-td patent-date-value">Dec 22, 2009</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7655692">US7655692</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2004</td><td class="patent-data-table-td patent-date-value">Feb 2, 2010</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Dissolving atorvastatin in alcoholic solvent comprising methanol, ethanol, 1-propanol, or isopropanol; high speed evaporation by spray drying</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7671216">US7671216</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2006</td><td class="patent-data-table-td patent-date-value">Mar 2, 2010</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Avoiding selective hydrolysis of methyl ester in the presence of tert-butyl ester by using a mineral aid simultaneously to induce acid-catalyzed cleavageof ketal and the hydroxy protecting group; avoid the use of air- and moisture-sensitive reagents; cost efficiency; simplification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7674913">US7674913</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2004</td><td class="patent-data-table-td patent-date-value">Mar 9, 2010</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Heterocyclic boronic acid compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7674923">US7674923</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2005</td><td class="patent-data-table-td patent-date-value">Mar 9, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd</td><td class="patent-data-table-td ">atorvastatin calcium epoxide dihydroxy (AED) is described; AED can be used as a standard or marker in determining the amount of AED in a sample</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7709647">US7709647</a></td><td class="patent-data-table-td patent-date-value">Apr 17, 2008</td><td class="patent-data-table-td patent-date-value">May 4, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Antagonists or inverse agonists of the CB-1 receptor; metabolic and eating disorders, dementia, substance abuse; e.g. N-(1-benzyl-6-(4-fluorophenyl)-1,2,3,4-tetrahydroquinolin-3-yl)-3-phenylpropanamide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732465">US7732465</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2008</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Novartis Vaccines And Diagnostics, Inc.</td><td class="patent-data-table-td ">{1-Methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine; inhibitors of kinase/Raf kinase activity associated with tumorigenesis, serine/threonine kinase or receptor tyrosine kinase; cancer; tumors; inhibit MAPK signaling pathway</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732623">US7732623</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2008</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Form V, having improved water solubility over Form 1; formed by dissolving a metal, ammonium or alkylammonium salt of atorvastatin in a solvent, contacting with a calcium salt and isolating</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7763278">US7763278</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 2003</td><td class="patent-data-table-td patent-date-value">Jul 27, 2010</td><td class="patent-data-table-td ">Elan Pharma International Ltd.</td><td class="patent-data-table-td ">As cholesterol lowering agents and for treatment of cardiovascular disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7767820">US7767820</a></td><td class="patent-data-table-td patent-date-value">May 5, 2008</td><td class="patent-data-table-td patent-date-value">Aug 3, 2010</td><td class="patent-data-table-td ">Novartis Vaccines And Diagnostics, Inc.</td><td class="patent-data-table-td ">such as {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)-amine via reduction, desulfurization; for treating kinase mediated disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7767828">US7767828</a></td><td class="patent-data-table-td patent-date-value">May 1, 2006</td><td class="patent-data-table-td patent-date-value">Aug 3, 2010</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">preferential dipeptidyl peptidase-IV inhibitors such as (2R)-1-{2-[(3S)-Pyrrolidin- 3-methyl-3-ylamino]- acetyl}-pyrrolidine-2- boronic acid, used as antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7786163">US7786163</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2005</td><td class="patent-data-table-td patent-date-value">Aug 31, 2010</td><td class="patent-data-table-td ">Forest Laboratories Holdings Limited (BM)</td><td class="patent-data-table-td ">such as 6-Amino-5-oxo-hexahydro-pyrrolo[2,1-b]thiazole-3-carbonitrile hydrochloride, useful as Dipeptidyl peptidase-IV inhibitors, for the treatment of diabetes, hyperglycemia, Syndrome X, obesity, atherosclerosis, inflammatory bowel disease and as immunology modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790197">US7790197</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2004</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Wet granulated particle form; compression; milling; benign prostate hyperplasia ; anticholesterol agents; antilipemic agents; Alzheimer&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7795436">US7795436</a></td><td class="patent-data-table-td patent-date-value">Aug 24, 2006</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">cis-6-(2,4-Dichloro-phenyl)-1,2,3,4,4a,9a-hexahydro-3-aza-fluoren-9-one, used for treating metabolic disorders, nervous system disorders, headaches, gastrointestinal disorders and as analgesics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7812048">US7812048</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Oct 12, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">N-[3-[(2S)-1-methoxypropan-2-yl]oxy-5-(4-methylsulfonylphenoxy)phenyl]-1H-imidazole-5-carboxamide, used as antidiabetic agents, especially for the treatment of non-insulin dependent diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7812179">US7812179</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 2008</td><td class="patent-data-table-td patent-date-value">Oct 12, 2010</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Preparing 5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3hydroxyl-1-pentanoic acid 7 by reacting aldehyde with 2-hydroxy-1,2,2-triphenylethyl acetate and a chelating cosolvent; hydrolysis; carboxylation by reaction with base; salt formation, purification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7816347">US7816347</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2005</td><td class="patent-data-table-td patent-date-value">Oct 19, 2010</td><td class="patent-data-table-td ">Solvay Pharmaceuticals Gmbh</td><td class="patent-data-table-td ">dual acting compound which acts as a neutral endopeptidase-inhibitor and as an inhibitor of the endogenous endothelin producing system and is selected from daglutril and at least one HMG CoA reductase inhibitor selected from atorvastatin, pravastatin, simvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7825139">US7825139</a></td><td class="patent-data-table-td patent-date-value">May 25, 2006</td><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td ">Forest Laboratories Holdings Limited (BM)</td><td class="patent-data-table-td ">Compounds and methods for selective inhibition of dipeptidyl peptidase-IV</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7834195">US7834195</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2007</td><td class="patent-data-table-td patent-date-value">Nov 16, 2010</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Adding atorvastatin calcium to propylene glycol/1,2-/; adding an organic cosolvent; optionally adding water; isolating and drying by filtration; crystallization; stability, moisturizer for drugs, cosmetics, foods, tobacco products, humectant food additives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7858639">US7858639</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2009</td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">[1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7872154">US7872154</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 2008</td><td class="patent-data-table-td patent-date-value">Jan 18, 2011</td><td class="patent-data-table-td ">Arch Pharmalabs Limited</td><td class="patent-data-table-td ">Reacting 2-halo-1-(4-fluorophenyl)-2-phenone of formula II with 4-methyl-3-oxo-N-phenylpentamide; high purity and good yield; for the synthesis of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7875731">US7875731</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2005</td><td class="patent-data-table-td patent-date-value">Jan 25, 2011</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884217">US7884217</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2007</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7893252">US7893252</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 2008</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">Pro-Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Selectively depolymerized galactomannan polysaccharide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7906658">US7906658</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2007</td><td class="patent-data-table-td patent-date-value">Mar 15, 2011</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7923467">US7923467</a></td><td class="patent-data-table-td patent-date-value">May 28, 2004</td><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories, Inc.</td><td class="patent-data-table-td ">Substituted pyrrole derivatives and their use as HMG-CO inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7939675">US7939675</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2005</td><td class="patent-data-table-td patent-date-value">May 10, 2011</td><td class="patent-data-table-td ">Pfizer, Inc.</td><td class="patent-data-table-td ">dissolving atorvastatin in a nonalcoholic solvent such as dimethylsulfoxide to form a solution; and lyophilizing the solution to form amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7943656">US7943656</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2008</td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Crystal forms of saxagliptin and processes for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7956049">US7956049</a></td><td class="patent-data-table-td patent-date-value">May 15, 2009</td><td class="patent-data-table-td patent-date-value">Jun 7, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Melanin concentrating hormone receptor-1 antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7956198">US7956198</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2006</td><td class="patent-data-table-td patent-date-value">Jun 7, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories, Limited</td><td class="patent-data-table-td ">Pharmaceutical compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7956214">US7956214</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 2009</td><td class="patent-data-table-td patent-date-value">Jun 7, 2011</td><td class="patent-data-table-td ">Karo Bio Ab</td><td class="patent-data-table-td ">Process for the preparation of aniline-derived thyroid receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7960349">US7960349</a></td><td class="patent-data-table-td patent-date-value">May 25, 2007</td><td class="patent-data-table-td patent-date-value">Jun 14, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">N-terminally modified GLP-1 receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7989433">US7989433</a></td><td class="patent-data-table-td patent-date-value">May 28, 2009</td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7998986">US7998986</a></td><td class="patent-data-table-td patent-date-value">Dec 20, 2002</td><td class="patent-data-table-td patent-date-value">Aug 16, 2011</td><td class="patent-data-table-td ">Exelixis Patent Company Llc</td><td class="patent-data-table-td ">Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8012984">US8012984</a></td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8013001">US8013001</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 17, 2008</td><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">Exelixis, Inc.</td><td class="patent-data-table-td ">Modulators of LXR</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8017647">US8017647</a></td><td class="patent-data-table-td patent-date-value">Aug 15, 2006</td><td class="patent-data-table-td patent-date-value">Sep 13, 2011</td><td class="patent-data-table-td ">Arrow International Limited</td><td class="patent-data-table-td ">Crystalline sodium atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8026376">US8026376</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2005</td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td ">Pfizer, Inc.</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8026377">US8026377</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2006</td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories, Limited</td><td class="patent-data-table-td ">Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8067420">US8067420</a></td><td class="patent-data-table-td patent-date-value">Feb 16, 2011</td><td class="patent-data-table-td patent-date-value">Nov 29, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8071638">US8071638</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 2009</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Solid states of atorvastatin potassium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8080672">US8080672</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2006</td><td class="patent-data-table-td patent-date-value">Dec 20, 2011</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Crystal form of atorvastatin hemi-calcium and processes for preparation thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084488">US8084488</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2006</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097734">US8097734</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 15, 2006</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Arrow International Limited</td><td class="patent-data-table-td ">Crystalline sodium atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8115015">US8115015</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2009</td><td class="patent-data-table-td patent-date-value">Feb 14, 2012</td><td class="patent-data-table-td ">Cadila Healthcare Limited</td><td class="patent-data-table-td ">Process for the preparation of amorphous atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8158362">US8158362</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2005</td><td class="patent-data-table-td patent-date-value">Apr 17, 2012</td><td class="patent-data-table-td ">Decode Genetics Ehf.</td><td class="patent-data-table-td ">Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8158677">US8158677</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2008</td><td class="patent-data-table-td patent-date-value">Apr 17, 2012</td><td class="patent-data-table-td ">The Trustees Of Princeton University</td><td class="patent-data-table-td ">Treatment of viral infections by modulation of host cell metabolic pathways</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8163959">US8163959</a></td><td class="patent-data-table-td patent-date-value">Nov 11, 2010</td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td ">Arch Pharmalabs Limited</td><td class="patent-data-table-td ">Reacting 2-halo-1-(4-fluorophenyl)-2-phenone of formula II with 4-methyl-3-oxo-N-phenylpentamide; high purity and good yield; for the synthesis of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8173689">US8173689</a></td><td class="patent-data-table-td patent-date-value">May 8, 2009</td><td class="patent-data-table-td patent-date-value">May 8, 2012</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8188300">US8188300</a></td><td class="patent-data-table-td patent-date-value">Nov 15, 2010</td><td class="patent-data-table-td patent-date-value">May 29, 2012</td><td class="patent-data-table-td ">Apotex Pharmachem Inc.</td><td class="patent-data-table-td ">Atorvastatin calcium propylene glycol solvates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8236847">US8236847</a></td><td class="patent-data-table-td patent-date-value">Apr 6, 2011</td><td class="patent-data-table-td patent-date-value">Aug 7, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Crystal forms of saxagliptin and processes for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8236966">US8236966</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2010</td><td class="patent-data-table-td patent-date-value">Aug 7, 2012</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, alpha-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8258315">US8258315</a></td><td class="patent-data-table-td patent-date-value">Apr 4, 2011</td><td class="patent-data-table-td patent-date-value">Sep 4, 2012</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Process for forming amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263659">US8263659</a></td><td class="patent-data-table-td patent-date-value">May 21, 2009</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Thyroid receptor ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8273777">US8273777</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2010</td><td class="patent-data-table-td patent-date-value">Sep 25, 2012</td><td class="patent-data-table-td ">Bristol-Meyer Squibb Company</td><td class="patent-data-table-td ">Glucokinase activators and methods of using same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329922">US8329922</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 2011</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">Arrow International Limited</td><td class="patent-data-table-td ">Crystalline sodium atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8354446">US8354446</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2008</td><td class="patent-data-table-td patent-date-value">Jan 15, 2013</td><td class="patent-data-table-td ">Ligand Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Selective androgen receptor modulators (SARMs) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8383667">US8383667</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2011</td><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">Warner Lambert Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8415295">US8415295</a></td><td class="patent-data-table-td patent-date-value">Jan 22, 2010</td><td class="patent-data-table-td patent-date-value">Apr 9, 2013</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Heterocyclic boronic acid compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8415364">US8415364</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2004</td><td class="patent-data-table-td patent-date-value">Apr 9, 2013</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Method of preventing or treating glaucoma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440712">US8440712</a></td><td class="patent-data-table-td patent-date-value">May 20, 2011</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Arrow International Limited</td><td class="patent-data-table-td ">Crystalline sodium atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8497370">US8497370</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td patent-date-value">Jul 30, 2013</td><td class="patent-data-table-td ">Kaohsiung Medical University</td><td class="patent-data-table-td ">Processes for preparing amine salts of sildenafil-analogues and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8513412">US8513412</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">RedX Pharna Limited</td><td class="patent-data-table-td ">Rosuvastatin and atorvastatin derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8552207">US8552207</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2012</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8563750">US8563750</a></td><td class="patent-data-table-td patent-date-value">Aug 22, 2011</td><td class="patent-data-table-td patent-date-value">Oct 22, 2013</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8592459">US8592459</a></td><td class="patent-data-table-td patent-date-value">Apr 13, 2010</td><td class="patent-data-table-td patent-date-value">Nov 26, 2013</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Substituted benzimidazoles and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8618115">US8618115</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 2006</td><td class="patent-data-table-td patent-date-value">Dec 31, 2013</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8648109">US8648109</a></td><td class="patent-data-table-td patent-date-value">Jan 22, 2013</td><td class="patent-data-table-td patent-date-value">Feb 11, 2014</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8673881">US8673881</a></td><td class="patent-data-table-td patent-date-value">Apr 13, 2010</td><td class="patent-data-table-td patent-date-value">Mar 18, 2014</td><td class="patent-data-table-td ">A.T. Resolve Sarl</td><td class="patent-data-table-td ">Compositions and methods for the treatment of inflammation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8686163">US8686163</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 2012</td><td class="patent-data-table-td patent-date-value">Apr 1, 2014</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Process for forming amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8710048">US8710048</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2012</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8748633">US8748633</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2012</td><td class="patent-data-table-td patent-date-value">Jun 10, 2014</td><td class="patent-data-table-td ">Ligand Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Selective androgen receptor modulators (SARMs) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8778927">US8778927</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 2009</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Smoothened antagonism for the treatment of hedgehog pathway-related disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110183962">US20110183962</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 28, 2009</td><td class="patent-data-table-td patent-date-value">Jul 28, 2011</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Smoothened antagonism for the treatment of hedgehog pathway-related disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE40667">USRE40667</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2007</td><td class="patent-data-table-td patent-date-value">Mar 17, 2009</td><td class="patent-data-table-td ">Warner-Lambert Company Llc</td><td class="patent-data-table-td ">[R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CN101090718B?cl=en">CN101090718B</a></td><td class="patent-data-table-td patent-date-value">Dec 28, 2005</td><td class="patent-data-table-td patent-date-value">Nov 10, 2010</td><td class="patent-data-table-td ">韩美药品株式会社</td><td class="patent-data-table-td ">Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0306929A2?cl=en">EP0306929A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 7, 1988</td><td class="patent-data-table-td patent-date-value">Mar 15, 1989</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">6-[[(Substituted)pyridin-3-YL]alkyl]-and alkenyl]-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0308736A2?cl=en">EP0308736A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 8, 1988</td><td class="patent-data-table-td patent-date-value">Mar 29, 1989</td><td class="patent-data-table-td ">Nissan Chemical Industries Ltd.</td><td class="patent-data-table-td ">Pyrimidine type mevalonolactones</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0319847A2?cl=en">EP0319847A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 1, 1988</td><td class="patent-data-table-td patent-date-value">Jun 14, 1989</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">Method for the preparation of optically active 3-desmethylmevalonic acid derivatives and intermediate compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0324347A2?cl=en">EP0324347A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 3, 1989</td><td class="patent-data-table-td patent-date-value">Jul 19, 1989</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">3,5-Dihydroxycarboxylic acids and their derivatives, process for their preparation, their use as medicines, pharmaceutical compositions and intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0325129A2?cl=en">EP0325129A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 9, 1989</td><td class="patent-data-table-td patent-date-value">Jul 26, 1989</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Disubstituted pyridines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0325130A2?cl=en">EP0325130A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 9, 1989</td><td class="patent-data-table-td patent-date-value">Jul 26, 1989</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Substituted pyridines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0330172A2?cl=en">EP0330172A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 22, 1989</td><td class="patent-data-table-td patent-date-value">Aug 30, 1989</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0354418A2?cl=en">EP0354418A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 28, 1989</td><td class="patent-data-table-td patent-date-value">Feb 14, 1990</td><td class="patent-data-table-td ">Hoechst Aktiengesellschaft</td><td class="patent-data-table-td ">6-Fluoro-3,5-dihydroxycarboxylic acids and their derivatives, processes for their preparation, their use as medicaments, pharmaceutical preparations and intermediates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0409281A1?cl=en">EP0409281A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 20, 1990</td><td class="patent-data-table-td patent-date-value">Jan 23, 1991</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">(R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0680963A1?cl=en">EP0680963A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 3, 1995</td><td class="patent-data-table-td patent-date-value">Nov 8, 1995</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">(Hydroxyphenylamino)carbonyl pyrroles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1061073A1?cl=en">EP1061073A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 20, 1990</td><td class="patent-data-table-td patent-date-value">Dec 20, 2000</td><td class="patent-data-table-td ">Warner-Lambert Company</td><td class="patent-data-table-td ">(R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1123924A1?cl=en">EP1123924A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 9, 1989</td><td class="patent-data-table-td patent-date-value">Aug 16, 2001</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Substituted pyridines as HMG-COA reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1123925A1?cl=en">EP1123925A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 9, 1989</td><td class="patent-data-table-td patent-date-value">Aug 16, 2001</td><td class="patent-data-table-td ">Bayer Ag</td><td class="patent-data-table-td ">Process for preparation of substituted pyridines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1734034A2?cl=en">EP1734034A2</a></td><td class="patent-data-table-td patent-date-value">Dec 27, 2001</td><td class="patent-data-table-td patent-date-value">Dec 20, 2006</td><td class="patent-data-table-td ">Warner-Lambert Company LLC</td><td class="patent-data-table-td ">Carboxylic acid salts of beta-alanine esters or -amides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1808162A1?cl=en">EP1808162A1</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2005</td><td class="patent-data-table-td patent-date-value">Jul 18, 2007</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Atorvastatin pharmaceutical formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1810667A1?cl=en">EP1810667A1</a></td><td class="patent-data-table-td patent-date-value">Jan 20, 2006</td><td class="patent-data-table-td patent-date-value">Jul 25, 2007</td><td class="patent-data-table-td ">KRKA, tovarna zdravil, d.d., Novo mesto</td><td class="patent-data-table-td ">Pharmaceutical composition comprising amorphous atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1923057A1?cl=en">EP1923057A1</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2005</td><td class="patent-data-table-td patent-date-value">May 21, 2008</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd</td><td class="patent-data-table-td ">Atorvastatin pharmaceutical formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1961419A1?cl=en">EP1961419A1</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2003</td><td class="patent-data-table-td patent-date-value">Aug 27, 2008</td><td class="patent-data-table-td ">Pfizer Products Inc.</td><td class="patent-data-table-td ">Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1977738A1?cl=en">EP1977738A1</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2004</td><td class="patent-data-table-td patent-date-value">Oct 8, 2008</td><td class="patent-data-table-td ">Warner-Lambert Company LLC</td><td class="patent-data-table-td ">Pharmaceutical compositions comprising atorvastatin manufactured without granulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1997489A1?cl=en">EP1997489A1</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2004</td><td class="patent-data-table-td patent-date-value">Dec 3, 2008</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1997533A1?cl=en">EP1997533A1</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2004</td><td class="patent-data-table-td patent-date-value">Dec 3, 2008</td><td class="patent-data-table-td ">Phenomix Corporation</td><td class="patent-data-table-td ">Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2192112A1?cl=en">EP2192112A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 2, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Process for preparing atorvastatin hemi-calcium Form I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2192113A1?cl=en">EP2192113A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 2, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Novel crystal form XI of atorvastatin hemi-calcium and processes for its preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2194041A1?cl=en">EP2194041A1</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 9, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Novel crystal form IX of atorvastatin hemi-calcium and processes for its preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2206497A1?cl=en">EP2206497A1</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2000</td><td class="patent-data-table-td patent-date-value">Jul 14, 2010</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Polymorphic form of atorvastatin calcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2240442A2?cl=en">EP2240442A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 4, 2008</td><td class="patent-data-table-td patent-date-value">Oct 20, 2010</td><td class="patent-data-table-td ">Medichem Korea. Co., Ltd.</td><td class="patent-data-table-td ">Preparation process useful in synthesis of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2272825A2?cl=en">EP2272825A2</a></td><td class="patent-data-table-td patent-date-value">Mar 5, 2001</td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2298776A1?cl=en">EP2298776A1</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2006</td><td class="patent-data-table-td patent-date-value">Mar 23, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2319843A1?cl=en">EP2319843A1</a></td><td class="patent-data-table-td patent-date-value">May 28, 2004</td><td class="patent-data-table-td patent-date-value">May 11, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Substituted pyrrole derivatives and their use as HMG-CO inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336120A1?cl=en">EP2336120A1</a></td><td class="patent-data-table-td patent-date-value">Jan 8, 2008</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L.</td><td class="patent-data-table-td ">Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2420488A1?cl=en">EP2420488A1</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2011</td><td class="patent-data-table-td patent-date-value">Feb 22, 2012</td><td class="patent-data-table-td ">Kyongbo pharmaceutical, Co., Ltd</td><td class="patent-data-table-td ">Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2428516A1?cl=en">EP2428516A1</a></td><td class="patent-data-table-td patent-date-value">Nov 19, 2004</td><td class="patent-data-table-td patent-date-value">Mar 14, 2012</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Novel phosphorus-containing thyromimetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2452683A2?cl=en">EP2452683A2</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td patent-date-value">May 16, 2012</td><td class="patent-data-table-td ">Amgen Inc.</td><td class="patent-data-table-td ">Methods for treating atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2457918A2?cl=en">EP2457918A2</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2007</td><td class="patent-data-table-td patent-date-value">May 30, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2474549A1?cl=en">EP2474549A1</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 2008</td><td class="patent-data-table-td patent-date-value">Jul 11, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2481726A2?cl=en">EP2481726A2</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2008</td><td class="patent-data-table-td patent-date-value">Aug 1, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Crystal forms of saxagliptin and processes for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2487154A1?cl=en">EP2487154A1</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2006</td><td class="patent-data-table-td patent-date-value">Aug 15, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2489656A1?cl=en">EP2489656A1</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2008</td><td class="patent-data-table-td patent-date-value">Aug 22, 2012</td><td class="patent-data-table-td ">Ligand Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Selective androgen receptor modulators (sarms) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2489730A1?cl=en">EP2489730A1</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Aug 22, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2489731A1?cl=en">EP2489731A1</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Aug 22, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2522721A2?cl=en">EP2522721A2</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2008</td><td class="patent-data-table-td patent-date-value">Nov 14, 2012</td><td class="patent-data-table-td ">Amgen, Inc</td><td class="patent-data-table-td ">Modified lecithin-cholesterol acyltransferase enzymes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2527317A1?cl=en">EP2527317A1</a></td><td class="patent-data-table-td patent-date-value">Aug 23, 2007</td><td class="patent-data-table-td patent-date-value">Nov 28, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2527337A1?cl=en">EP2527337A1</a></td><td class="patent-data-table-td patent-date-value">Apr 12, 2006</td><td class="patent-data-table-td patent-date-value">Nov 28, 2012</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Inhibitors of 11-beta hydroxysteroid dehydrogenase type I</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2540704A2?cl=en">EP2540704A2</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2005</td><td class="patent-data-table-td patent-date-value">Jan 2, 2013</td><td class="patent-data-table-td ">Pfizer Products Inc.</td><td class="patent-data-table-td ">Benethamine salt forms of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2572712A2?cl=en">EP2572712A2</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2008</td><td class="patent-data-table-td patent-date-value">Mar 27, 2013</td><td class="patent-data-table-td ">The Trustees Of Princeton University</td><td class="patent-data-table-td ">Treatment of viral infections by modulation of host cell metabolic pathways</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2581081A2?cl=en">EP2581081A2</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2008</td><td class="patent-data-table-td patent-date-value">Apr 17, 2013</td><td class="patent-data-table-td ">The Trustees Of Princeton University</td><td class="patent-data-table-td ">Treatment of viral infections by modulation of host cell metabolic pathways</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2614822A2?cl=en">EP2614822A2</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td patent-date-value">Jul 17, 2013</td><td class="patent-data-table-td ">Redx Pharma Limited</td><td class="patent-data-table-td ">Atorvastatin Derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2698157A1?cl=en">EP2698157A1</a></td><td class="patent-data-table-td patent-date-value">Sep 18, 2007</td><td class="patent-data-table-td patent-date-value">Feb 19, 2014</td><td class="patent-data-table-td ">Merck Sharp &amp; Dohme Corp.</td><td class="patent-data-table-td ">Method of treatment using fatty acid synthesis inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1989007598A2?cl=en">WO1989007598A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 22, 1989</td><td class="patent-data-table-td patent-date-value">Aug 24, 1989</td><td class="patent-data-table-td ">Warner Lambert Co</td><td class="patent-data-table-td ">Improved process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990010444A1?cl=en">WO1990010444A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 8, 1990</td><td class="patent-data-table-td patent-date-value">Sep 11, 1990</td><td class="patent-data-table-td ">Rorer Int Overseas</td><td class="patent-data-table-td ">NOVEL HMG-CoA REDUCTASE INHIBITORS</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1991004736A1?cl=en">WO1991004736A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 7, 1990</td><td class="patent-data-table-td patent-date-value">Apr 18, 1991</td><td class="patent-data-table-td ">Rorer Int Overseas</td><td class="patent-data-table-td ">SUBSTITUTED CYCLOHEXENE DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994016693A1?cl=en">WO1994016693A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 20, 1993</td><td class="patent-data-table-td patent-date-value">Aug 4, 1994</td><td class="patent-data-table-td ">Warner Lambert Co</td><td class="patent-data-table-td ">Stable oral ci-981 formulation and process of preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994020492A1?cl=en">WO1994020492A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 24, 1994</td><td class="patent-data-table-td patent-date-value">Sep 15, 1994</td><td class="patent-data-table-td ">Warner Lambert Co</td><td class="patent-data-table-td ">Novel process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004005250A1?cl=en">WO2004005250A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 8, 2003</td><td class="patent-data-table-td patent-date-value">Jan 15, 2004</td><td class="patent-data-table-td ">Ram Chander Aryan</td><td class="patent-data-table-td ">Hmg-coa reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004105752A1?cl=en">WO2004105752A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 28, 2004</td><td class="patent-data-table-td patent-date-value">Dec 9, 2004</td><td class="patent-data-table-td ">Yatendra Kumar</td><td class="patent-data-table-td ">Substituted pyrrole derivatives as hmg-coa reductase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004106299A2?cl=en">WO2004106299A2</a></td><td class="patent-data-table-td patent-date-value">May 28, 2004</td><td class="patent-data-table-td patent-date-value">Dec 9, 2004</td><td class="patent-data-table-td ">Ranbaxy Lab Ltd</td><td class="patent-data-table-td ">Substituted pyrrole derivatives and their use as hmg-co inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005019161A1?cl=en">WO2005019161A1</a></td><td class="patent-data-table-td patent-date-value">Aug 19, 2004</td><td class="patent-data-table-td patent-date-value">Mar 3, 2005</td><td class="patent-data-table-td ">Merck Frosst Canada Inc</td><td class="patent-data-table-td ">Cathepsin cysteine protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005026116A1?cl=en">WO2005026116A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 6, 2004</td><td class="patent-data-table-td patent-date-value">Mar 24, 2005</td><td class="patent-data-table-td ">Anthony Michael Campeta</td><td class="patent-data-table-td ">Crystalline forms of `r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005105738A2?cl=en">WO2005105738A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 25, 2005</td><td class="patent-data-table-td patent-date-value">Nov 10, 2005</td><td class="patent-data-table-td ">Pfizer Prod Inc</td><td class="patent-data-table-td ">Salt forms of atorvastatin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006019886A2?cl=en">WO2006019886A2</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 2005</td><td class="patent-data-table-td patent-date-value">Feb 23, 2006</td><td class="patent-data-table-td ">Saleem Ahmad</td><td class="patent-data-table-td ">Pyrrolo(oxo)isoquinolines as 5ht ligands</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006045018A1?cl=en">WO2006045018A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2005</td><td class="patent-data-table-td patent-date-value">Apr 27, 2006</td><td class="patent-data-table-td ">Teva Pharma</td><td class="patent-data-table-td ">Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006054308A2?cl=en">WO2006054308A2</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2005</td><td class="patent-data-table-td patent-date-value">May 26, 2006</td><td class="patent-data-table-td ">Dexcel Pharma Technologies Ltd</td><td class="patent-data-table-td ">Stable atorvastatin formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006123182A2?cl=en">WO2006123182A2</a></td><td class="patent-data-table-td patent-date-value">May 16, 2006</td><td class="patent-data-table-td patent-date-value">Nov 23, 2006</td><td class="patent-data-table-td ">Merck Sharp &amp; Dohme</td><td class="patent-data-table-td ">Cyclohexyl sulphones for treatment of cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007053819A2?cl=en">WO2007053819A2</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2006</td><td class="patent-data-table-td patent-date-value">May 10, 2007</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007073503A2?cl=en">WO2007073503A2</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2006</td><td class="patent-data-table-td patent-date-value">Jun 28, 2007</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007074406A2?cl=en">WO2007074406A2</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2006</td><td class="patent-data-table-td patent-date-value">Jul 5, 2007</td><td class="patent-data-table-td ">Pharmena North America Inc</td><td class="patent-data-table-td ">Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007118873A2?cl=en">WO2007118873A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 16, 2007</td><td class="patent-data-table-td patent-date-value">Oct 25, 2007</td><td class="patent-data-table-td ">Krka Tovarna Zdravil D D Novo</td><td class="patent-data-table-td ">Polymorphs of atorvastatin sodium and magnesium salts</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007139589A1?cl=en">WO2007139589A1</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2006</td><td class="patent-data-table-td patent-date-value">Dec 6, 2007</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">Sustained release glp-1 receptor modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008002591A2?cl=en">WO2008002591A2</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 2007</td><td class="patent-data-table-td patent-date-value">Jan 3, 2008</td><td class="patent-data-table-td ">Amgen Inc</td><td class="patent-data-table-td ">Methods for treating atherosclerosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008006043A2?cl=en">WO2008006043A2</a></td><td class="patent-data-table-td patent-date-value">Jul 6, 2007</td><td class="patent-data-table-td patent-date-value">Jan 10, 2008</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008057862A2?cl=en">WO2008057862A2</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2007</td><td class="patent-data-table-td patent-date-value">May 15, 2008</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-&amp;kappav;B ACTIVITY AND USE THEREOF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008102563A1?cl=en">WO2008102563A1</a></td><td class="patent-data-table-td patent-date-value">Feb 22, 2008</td><td class="patent-data-table-td patent-date-value">Aug 28, 2008</td><td class="patent-data-table-td ">Next21 Kk</td><td class="patent-data-table-td ">Therapeutic or prophylactic agent for vasoconstriction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008106692A1?cl=en">WO2008106692A1</a></td><td class="patent-data-table-td patent-date-value">Mar 3, 2008</td><td class="patent-data-table-td patent-date-value">Sep 4, 2008</td><td class="patent-data-table-td ">Novartis Vaccines &amp; Diagnostic</td><td class="patent-data-table-td ">Pim kinase inhibitors and methods of their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008139703A1?cl=en">WO2008139703A1</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2008</td><td class="patent-data-table-td patent-date-value">Nov 20, 2008</td><td class="patent-data-table-td ">Univ Kyushu Nat Univ Corp</td><td class="patent-data-table-td ">Agent for treatment of pulmonary disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008144062A1?cl=en">WO2008144062A1</a></td><td class="patent-data-table-td patent-date-value">May 20, 2008</td><td class="patent-data-table-td patent-date-value">Nov 27, 2008</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Csf-1r inhibitors, compositions, and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009058944A2?cl=en">WO2009058944A2</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2008</td><td class="patent-data-table-td patent-date-value">May 7, 2009</td><td class="patent-data-table-td ">Squibb Bristol Myers Co</td><td class="patent-data-table-td ">Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010093601A1?cl=en">WO2010093601A1</a></td><td class="patent-data-table-td patent-date-value">Feb 9, 2010</td><td class="patent-data-table-td patent-date-value">Aug 19, 2010</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Novel sulfonic acid-containing thyromimetics, and methods for their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010103318A1?cl=en">WO2010103318A1</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td patent-date-value">Sep 16, 2010</td><td class="patent-data-table-td ">Bradford Pharma Limited</td><td class="patent-data-table-td ">Rosuvastatin and atorvastatin derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010103319A1?cl=en">WO2010103319A1</a></td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td patent-date-value">Sep 16, 2010</td><td class="patent-data-table-td ">Bradford Pharma Limited</td><td class="patent-data-table-td ">Use of atorvastatin lactols as medicaments</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010111665A1?cl=en">WO2010111665A1</a></td><td class="patent-data-table-td patent-date-value">Mar 26, 2010</td><td class="patent-data-table-td patent-date-value">Sep 30, 2010</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011060255A1?cl=en">WO2011060255A1</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2010</td><td class="patent-data-table-td patent-date-value">May 19, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Reduced mass metformin formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011060256A2?cl=en">WO2011060256A2</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2010</td><td class="patent-data-table-td patent-date-value">May 19, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Bilayer tablet formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011060290A2?cl=en">WO2011060290A2</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2010</td><td class="patent-data-table-td patent-date-value">May 19, 2011</td><td class="patent-data-table-td ">Bristol-Myer Squibb Company</td><td class="patent-data-table-td ">Immediate release tablet formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011088806A2?cl=en">WO2011088806A2</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td patent-date-value">Jul 28, 2011</td><td class="patent-data-table-td ">Zentiva, K.S.</td><td class="patent-data-table-td ">A method of industrial production of an amorphous form of atorvastatin with a high specific surface area and its use in a dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011109333A1?cl=en">WO2011109333A1</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2011</td><td class="patent-data-table-td patent-date-value">Sep 9, 2011</td><td class="patent-data-table-td ">Lexicon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011130459A1?cl=en">WO2011130459A1</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 2011</td><td class="patent-data-table-td patent-date-value">Oct 20, 2011</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Novel glucokinase activators and methods of using same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012094293A1?cl=en">WO2012094293A1</a></td><td class="patent-data-table-td patent-date-value">Jan 3, 2012</td><td class="patent-data-table-td patent-date-value">Jul 12, 2012</td><td class="patent-data-table-td ">Lexicon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012145471A1?cl=en">WO2012145471A1</a></td><td class="patent-data-table-td patent-date-value">Apr 19, 2012</td><td class="patent-data-table-td patent-date-value">Oct 26, 2012</td><td class="patent-data-table-td ">Merck Sharp &amp; Dohme Corp.</td><td class="patent-data-table-td ">Insulin-like growth factor-1 receptor inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013004591A1?cl=en">WO2013004591A1</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2012</td><td class="patent-data-table-td patent-date-value">Jan 10, 2013</td><td class="patent-data-table-td ">Dsm Sinochem Pharmaceuticals Netherlands B.V.</td><td class="patent-data-table-td ">Micronized crystals of atorvastatin hemicalcium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013072770A2?cl=en">WO2013072770A2</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2012</td><td class="patent-data-table-td patent-date-value">May 23, 2013</td><td class="patent-data-table-td ">Dr. Reddy&#39;s Laboratories Ltd.</td><td class="patent-data-table-td ">Pharmaceutical formulations comprising atorvastatin and glimepiride</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013086443A1?cl=en">WO2013086443A1</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2012</td><td class="patent-data-table-td patent-date-value">Jun 13, 2013</td><td class="patent-data-table-td ">Amgen Inc.</td><td class="patent-data-table-td ">Agonistic human lcat antigen binding proteins and their use in therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2014081660A1?cl=en">WO2014081660A1</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2013</td><td class="patent-data-table-td patent-date-value">May 30, 2014</td><td class="patent-data-table-td ">Lexicon Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Inhibitors of sodium glucose cotransporter 1</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S422000">514/422</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc546/defs546.htm&usg=AFQjCNEVbqUa3Y2xdPcpKajVJNycCal0yg#C546S256000">546/256</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S537000">548/537</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S423000">514/423</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S517000">548/517</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc546/defs546.htm&usg=AFQjCNEVbqUa3Y2xdPcpKajVJNycCal0yg#C546S279100">546/279.1</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031402500">A61K31/4025</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031400000">A61K31/40</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0405060000">C07D405/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003060000">A61P3/06</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=SUMmBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07D405/06">C07D405/06</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07D405/06</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Aug 26, 2008</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-5 AND 8-9 IS CONFIRMED. CLAIMS 6 AND 7 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 13, 2008</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080222</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 18, 2007</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070702</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 17, 2007</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY LLC, NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CONVERSION TO LLC;ASSIGNOR:WARNER-LAMBERT COMPANY;REEL/FRAME:019562/0667</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20021231</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 8, 2003</td><td class="patent-data-table-td ">356</td><td class="patent-data-table-td ">Patent term extension under 35 u.s.c. 156</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">PRODUCT NAME: LIPITOR</span></div><div class="nested-key-value"><span class="nested-key">Expiry date: </span><span class="nested-value">20060530</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 29, 1998</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 18, 1998</td><td class="patent-data-table-td ">355A</td><td class="patent-data-table-td ">Patent term extension or patent term restoration according to 35 u.s.c. 155, 155a or 156</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">1,213 DAYS, EXPIRES: 20060530</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 23, 1994</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 31, 1990</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 30, 1986</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY, ANN ARBOR, MI., A CORP OF</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ROTH, BRUCE D.;REEL/FRAME:004561/0979</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19860530</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY,MICHIGAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROTH, BRUCE D.;REEL/FRAME:4561/979</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">WARNER-LAMBERT COMPANY, MICHIGAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROTH, BRUCE D.;REEL/FRAME:004561/0979</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U13I3jyXVqrl-TYxrawpFkfUFHIYw\u0026id=SUMmBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0VK78-UD9BZf8LRDVeuDtiCY_N_w\u0026id=SUMmBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2JBZPCuvndE_8ZzCkiIBLAagxZfg","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Trans_6_2_3_or_4_carboxamido_substituted.pdf?id=SUMmBAABERAJ\u0026output=pdf\u0026sig=ACfU3U1hT00gV_VFCpWCph61DmOpXFanxA"},"sample_url":"http://www.google.com/patents/reader?id=SUMmBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>